Conservatives for Patients' Rights commercial with the Doctor in England?
2008--- HCA International
Welcome to London's leading private hospitals- HCA International
Why we are London's No. 1 private hospital group- HCA International
� More than 3,000 top London and UK specialists in private practice- HCA International
No. 1 private hospital?- HCA International
This is what STUPID AMERICA gets:
LARGEST HEALTH CARE FRAUD CASE IN U.S. HISTORY SETTLED; HCA INVESTIGATION
Note: Hospital Corporation of America (HCA) was acquired by Columbia in 1994.
1997- As part of Richard Scott's severance package from Columbia he was paid $5.13 million and given a five year consulting contract at $950,000 per year.
1997+5 years consulting =2002
In 2002 FBI raided the offices of National Century Financial Enterprises in Dublin, Ohio.
National Century Financial Enterprises
Guess where ALL of Rick Scott’s Columbia homecare units were? National Century Financial Enterprises.
Largest fraud case the FBI has ever investigated-one acquittal- James K Happ, the ex-CFO of Columbia Homecare Group, Inc.
Jurors stated; "PROSECUTOR DID NOT DO HIS JOB"�hmm
Leo Wise , now at the ethics CBO ---jurors stated 'PROSECUTOR DID NOT DO HIS JOB'
"Ladies and gentlemen, this is a case of staggering fraud," 'It is one of the largest frauds the FBI has ever investigated. (Leo Wise )
The ONLY acquittal; James K Happ--the CFO of Columbia Homecare Group.
Leo Wise , (now at the ethics CBO) stated "Ladies and gentlemen, this is a case of staggering fraud," 'It is one of the largest frauds the FBI has ever investigated.
Then- low and behold: December 18, 2008 The ONLY acquittal; James K Happ!...belief that federal prosecutors had not done their job, the juror said.
Columbia/HCA is a partnership of financier Richard Rainwater of Ft. Worth and lawyer Richard Scott. Scott was recently terminated by Darla Moore, the wife of Richard Rainwater.
Richard Rainwater, ex-partner of GW Bush with the Rangers
Leo Wise, now at the ethics CBO ---jurors stated 'PROSECUTOR DID NOT DO HIS JOB'
In 2002 FBI raided the offices of National Century Financial Enterprises in Dublin, Ohio
"This case is one of the largest corporate fraud investigations involving a privately held company headquartered in small town America," said Assistant Director Kenneth W. Kaiser of the FBI Criminal Investigative Division.
Richard Scott -- sometimes called "the Bill Gates of health care" -- quit as chairman of Columbia/HCA Healthcare Corp. amid a massive federal investigation into the Medicare billing, physician recruiting and home-care practices of the nation's largest for-profit health care company.
Columbia/HCA is a partnership of financier Richard Rainwater of Ft. Worth and lawyer Richard Scott. Scott was recently terminated by Darla Moore, the wife of Richard Rainwater.
Rainwater also owned a large stake in Magellan Health Care which controls Charter Medical. Magellan, run by Darla Moore, is the largest network of psychiatric hospitals in the country. They are becoming more and more involved in obtaining government money for services formerly not covered as health care, according to Fortune Magazine.
1997 - Columbia/HCA Healthcare Corp. - the nation's largest for-profit health care company
Showing posts with label Corporate Fraud. Show all posts
Showing posts with label Corporate Fraud. Show all posts
Thursday, May 28, 2009
Wednesday, April 15, 2009
Miami forensic accountant - Rachlin Fraud on the Fraud...incredible
A federal judge has sharply criticized a Miami forensic accountant overseeing a massive forfeiture stemming from a health care fraud, saying she placed her firm's financial interests ahead of her role as court-appointed receiver.
U.S. District Court Judge B. Avant Edenfield in Savannah, Ga., also criticized Miami-based Rachlin, saying the firm purposely refused to file tax returns until it was paid, racking up fines and penalties.
Marta Alfonso, a partner in the firm's advisory services division, was appointed receiver after Edenfield ordered convicted officials of Miami-based Bio-Med Plus to pay forfeiture, fines and restitution following their convictions for bilking state and federal agencies on expensive AIDS and hemophilia treatments that were never administered.
Alfonso became involved in the case early, testifying as a defense expert, and made the unusual transition to receiver. She did well, recovering $54.1 million thus far on the forfeiture order.
She hired Miami attorney Thomas Tew, one of Tew Cardenas' name partners, as her lawyer in the receivership and farmed out the tax services to her firm.
Alfonso ran into trouble with the judge after filing an emergency motion Feb. 4 to pay Rachlin. The motion was filed after a court-appointed monitor overseeing the forfeiture refused to pay the bill for tax preparation. The monitor cited cost overruns and late filings.
Alfonso told the court that Rachlin should be paid $191,354, of which $127,397 is outstanding. The monitor had set a $76,500 budget cap for the tax returns prepared by Rachlin.
In an April 7 order to show cause, Edenfield said that Alfonso demonstrated a clear conflict of interest by lobbying the monitor on behalf of her firm. "The receiver's conflict has burdened the receivership not only by enabling an excessive budget overrun and the incurrence of unnecessary expenses, but also by causing additional receiver's fees, monitor's fees and attorney fees," the judge wrote.
The judge issued the order after asking both the receiver and monitor to file detailed explanations. Edenfield said the monitor's response was supported by affidavits and other documentation while the receiver's filing by Tew Cardenas attorney Dennis Nowak "was both untimely and unresponsive."
A call to Rachlin for comment was not returned by deadline.
Alfonso is a salaried Rachlin employee who does not share in the firm's profits. She did not return phone calls for comment.
In his order, the judge noted that Alfonso defended her firm, acknowledging mistakes may have been made but saying it was an internal Rachlin issue. She also said the services were reasonably priced even though invoices were $100,000 over budget and late.
Speaking on her behalf, Tew said this is the first dispute between Alfonso and the monitor in three years since she was appointed. He said the receivership would respond to the show cause order by Friday.
Tew said it is commonplace for receivers to tap their own firms for tax services.
Attorneys who are appointed receivers regularly hire their own firms as legal counsel.
"There has been no wrongdoing," Tew said. "We do not believe there is a conflict."
The judge set a hearing for next Tuesday, April 21, so Alfonso can show cause why she should not be removed as receiver and why the court should not seek to recover any wasted assets.
Rachlin bills itself as one of the largest independent public accounting and advisory service firms in the Southeast with 25 partners and more than 225 professionals in South and Central Florida.
Bio-Med Plus was a medical supply company based in Miami and Savannah with about 100 employees. It was acquired by Novis Pharmaceuticals in 2007 after three top Bio-Med officials were accused of cheating users of life-saving blood products. The officials were prosecuted for health care fraud in Georgia, Florida and California.
In his order, Edenfield chastised Alfonso for submitting several bills from Rachlin, ranging from $98,992 to $171,379 for the same tax services. Rachlin filed late tax returns for the receivership for 2006 and 2007, incurring $231,226 in interest and penalties.
The monitor, Madison Associates of Woodbridge, Va., raised questions about the bills after a routine review from April through mid-September 2008.
"Through e-mails, memoranda, revised, re-revised and thrice-revised invoices, the receiver and Rachlin offered a stream of unresponsive and obfuscatory answers to the monitor's inquirers reminiscent of the 'Who's on First?' Abbott and Costello comedy routine," Edenfield wrote in his order.
In a series of e-mails last year, Alfonso declared "we have been paid nothing" for the 2007 tax services after giving blanket approval for a series of misstated and miscalculated Rachlin invoices. She later conceded invoices had been paid, Edenfield said.
Edenfield concluded Rachlin did little from April to July 2008.
"This inactivity suggests that Rachlin negligently allowed late penalties and interest to accrue while it waited for the receiver's collection of its fees in excess of the [$76,500] cap," Edenfield wrote.
The monitor suggested last September that an outside arbiter be engaged in resolving the conflict over the tax return issue with Rachlin, but Alfonso declined the recommendation, the judge's order said.
Alfonso proposed an independent review earlier this month of Rachlin's work to render an opinion on reasonable fees, Tew said.
Edenfield responded in his order, "The opportunity for such review, however, has come and gone."
U.S. District Court Judge B. Avant Edenfield in Savannah, Ga., also criticized Miami-based Rachlin, saying the firm purposely refused to file tax returns until it was paid, racking up fines and penalties.
Marta Alfonso, a partner in the firm's advisory services division, was appointed receiver after Edenfield ordered convicted officials of Miami-based Bio-Med Plus to pay forfeiture, fines and restitution following their convictions for bilking state and federal agencies on expensive AIDS and hemophilia treatments that were never administered.
Alfonso became involved in the case early, testifying as a defense expert, and made the unusual transition to receiver. She did well, recovering $54.1 million thus far on the forfeiture order.
She hired Miami attorney Thomas Tew, one of Tew Cardenas' name partners, as her lawyer in the receivership and farmed out the tax services to her firm.
Alfonso ran into trouble with the judge after filing an emergency motion Feb. 4 to pay Rachlin. The motion was filed after a court-appointed monitor overseeing the forfeiture refused to pay the bill for tax preparation. The monitor cited cost overruns and late filings.
Alfonso told the court that Rachlin should be paid $191,354, of which $127,397 is outstanding. The monitor had set a $76,500 budget cap for the tax returns prepared by Rachlin.
In an April 7 order to show cause, Edenfield said that Alfonso demonstrated a clear conflict of interest by lobbying the monitor on behalf of her firm. "The receiver's conflict has burdened the receivership not only by enabling an excessive budget overrun and the incurrence of unnecessary expenses, but also by causing additional receiver's fees, monitor's fees and attorney fees," the judge wrote.
The judge issued the order after asking both the receiver and monitor to file detailed explanations. Edenfield said the monitor's response was supported by affidavits and other documentation while the receiver's filing by Tew Cardenas attorney Dennis Nowak "was both untimely and unresponsive."
A call to Rachlin for comment was not returned by deadline.
Alfonso is a salaried Rachlin employee who does not share in the firm's profits. She did not return phone calls for comment.
In his order, the judge noted that Alfonso defended her firm, acknowledging mistakes may have been made but saying it was an internal Rachlin issue. She also said the services were reasonably priced even though invoices were $100,000 over budget and late.
Speaking on her behalf, Tew said this is the first dispute between Alfonso and the monitor in three years since she was appointed. He said the receivership would respond to the show cause order by Friday.
Tew said it is commonplace for receivers to tap their own firms for tax services.
Attorneys who are appointed receivers regularly hire their own firms as legal counsel.
"There has been no wrongdoing," Tew said. "We do not believe there is a conflict."
The judge set a hearing for next Tuesday, April 21, so Alfonso can show cause why she should not be removed as receiver and why the court should not seek to recover any wasted assets.
Rachlin bills itself as one of the largest independent public accounting and advisory service firms in the Southeast with 25 partners and more than 225 professionals in South and Central Florida.
Bio-Med Plus was a medical supply company based in Miami and Savannah with about 100 employees. It was acquired by Novis Pharmaceuticals in 2007 after three top Bio-Med officials were accused of cheating users of life-saving blood products. The officials were prosecuted for health care fraud in Georgia, Florida and California.
In his order, Edenfield chastised Alfonso for submitting several bills from Rachlin, ranging from $98,992 to $171,379 for the same tax services. Rachlin filed late tax returns for the receivership for 2006 and 2007, incurring $231,226 in interest and penalties.
The monitor, Madison Associates of Woodbridge, Va., raised questions about the bills after a routine review from April through mid-September 2008.
"Through e-mails, memoranda, revised, re-revised and thrice-revised invoices, the receiver and Rachlin offered a stream of unresponsive and obfuscatory answers to the monitor's inquirers reminiscent of the 'Who's on First?' Abbott and Costello comedy routine," Edenfield wrote in his order.
In a series of e-mails last year, Alfonso declared "we have been paid nothing" for the 2007 tax services after giving blanket approval for a series of misstated and miscalculated Rachlin invoices. She later conceded invoices had been paid, Edenfield said.
Edenfield concluded Rachlin did little from April to July 2008.
"This inactivity suggests that Rachlin negligently allowed late penalties and interest to accrue while it waited for the receiver's collection of its fees in excess of the [$76,500] cap," Edenfield wrote.
The monitor suggested last September that an outside arbiter be engaged in resolving the conflict over the tax return issue with Rachlin, but Alfonso declined the recommendation, the judge's order said.
Alfonso proposed an independent review earlier this month of Rachlin's work to render an opinion on reasonable fees, Tew said.
Edenfield responded in his order, "The opportunity for such review, however, has come and gone."
Friday, December 19, 2008
OIG Releases Reports on Hospital Adverse Events and State Reporting Systems
December 16, 2008
OIG Releases Reports on Hospital Adverse Events and State Reporting SystemsOn December 16, 2008, the Department of Health and Human Services' Office of Inspector General (OIG) released a report entitled "Adverse Events in Hospitals: Overview of Key Issues."
The Tax Relief and Health Care Act of 2006 (Act) mandates that the OIG report to Congress regarding the incidence of "never events" among Medicare beneficiaries, payment by Medicare or beneficiaries for services furnished in connection with such events, and the process that the Centers for Medicare & Medicaid Services uses to identify events and deny payment. According to the OIG, this report is one in a series to fulfill the requirements of the Act.
In this report, the OIG identifies 7 issues critical to understanding adverse events in hospitals. In brief, the 7 issues can be described as follows:
Estimates of the incidence of adverse events in hospitals vary widely and measurement is difficult.
Nonpayment policies for adverse events are gaining in prominence and are viewed as a powerful incentive to reduce incidence but raise potential drawbacks.
Hospitals rely on staff and managers to report adverse events internally, but barriers can inhibit reporting.
Hospitals report adverse events to various oversight entities, although stakeholders suspect substantial underreporting.
Public disclosure of adverse events can benefit patients but also raises legal concerns for patients and providers.
Information to help prevent adverse events is widely available, but some hospitals and clinicians may be slow to adopt or routinely apply recommended practices.
Interviews and literature reveal strategies that may accelerate progress in reducing the incidence of adverse events in hospitals.
On December 16, 2008, the OIG has also released a related report entitled "Adverse Events in Hospitals: State Reporting Systems" in which the OIG identifies and describes state adverse event reporting systems and how states use the reported information. In brief, the OIG reports the following:
As of January 2008, 26 states had hospital adverse event reporting systems and another state had taken action to develop one.
Reporting systems varied in terms of what events were reported, criteria used for selection, and type of information reported.
Most states with systems reported having mechanisms to identify underreporting and strategies to improve reporting.
23 states reported using data to hold individual hospitals accountable and 18 states reported using data to promote learning and prevent adverse events.
In this report, the OIG concludes that state systems are disparate making state adverse event reporting systems data unsuitable for use in the aggregate to identify national incidence and trends. However, the OIG reports that most states use the reported data in similar ways. For instance, states use reports to assess individual hospitals' responses to adverse events, and to promote learning and prevent adverse events.
For purposes of the OIG reports, the OIG expanded beyond the term "never events" to address "adverse events," which describe patient harm resulting from medical ca
http://medicareupdate.typepad.com/medicare_update/2008/12/oigadverseeventreports.html
OIG Releases Reports on Hospital Adverse Events and State Reporting SystemsOn December 16, 2008, the Department of Health and Human Services' Office of Inspector General (OIG) released a report entitled "Adverse Events in Hospitals: Overview of Key Issues."
The Tax Relief and Health Care Act of 2006 (Act) mandates that the OIG report to Congress regarding the incidence of "never events" among Medicare beneficiaries, payment by Medicare or beneficiaries for services furnished in connection with such events, and the process that the Centers for Medicare & Medicaid Services uses to identify events and deny payment. According to the OIG, this report is one in a series to fulfill the requirements of the Act.
In this report, the OIG identifies 7 issues critical to understanding adverse events in hospitals. In brief, the 7 issues can be described as follows:
Estimates of the incidence of adverse events in hospitals vary widely and measurement is difficult.
Nonpayment policies for adverse events are gaining in prominence and are viewed as a powerful incentive to reduce incidence but raise potential drawbacks.
Hospitals rely on staff and managers to report adverse events internally, but barriers can inhibit reporting.
Hospitals report adverse events to various oversight entities, although stakeholders suspect substantial underreporting.
Public disclosure of adverse events can benefit patients but also raises legal concerns for patients and providers.
Information to help prevent adverse events is widely available, but some hospitals and clinicians may be slow to adopt or routinely apply recommended practices.
Interviews and literature reveal strategies that may accelerate progress in reducing the incidence of adverse events in hospitals.
On December 16, 2008, the OIG has also released a related report entitled "Adverse Events in Hospitals: State Reporting Systems" in which the OIG identifies and describes state adverse event reporting systems and how states use the reported information. In brief, the OIG reports the following:
As of January 2008, 26 states had hospital adverse event reporting systems and another state had taken action to develop one.
Reporting systems varied in terms of what events were reported, criteria used for selection, and type of information reported.
Most states with systems reported having mechanisms to identify underreporting and strategies to improve reporting.
23 states reported using data to hold individual hospitals accountable and 18 states reported using data to promote learning and prevent adverse events.
In this report, the OIG concludes that state systems are disparate making state adverse event reporting systems data unsuitable for use in the aggregate to identify national incidence and trends. However, the OIG reports that most states use the reported data in similar ways. For instance, states use reports to assess individual hospitals' responses to adverse events, and to promote learning and prevent adverse events.
For purposes of the OIG reports, the OIG expanded beyond the term "never events" to address "adverse events," which describe patient harm resulting from medical ca
http://medicareupdate.typepad.com/medicare_update/2008/12/oigadverseeventreports.html
Thursday, December 18, 2008
"...recruited homeless people on Medicare and Medi-Cal for hospitalization."
The former head of City of Angels Medical Center pleaded guilty today to his part in a scheme that used L.A.’s Skid Row homeless to defraud Medicare and Medi-Cal. More from KPCC’s Debra Baer.
Debra Baer: Dr. Rudra Sabaratnam pleaded guilty in federal court to two felony counts of paying half-a-million dollars in illegal kickbacks for patient referrals. Prosecutors say he and a co-defendant, who also admitted guilt, recruited homeless people on Medicare and Medi-Cal for hospitalization, even though they weren’t sick. They then billed the government health programs for unnecessary medical care.
Sabaratnam agreed to pay more than $4 million in restitution to Medicare and Medi-Cal. The 64-year-old Brentwood physician faces up to 10 years in prison when he is sentenced in June.
Tools
Debra Baer: Dr. Rudra Sabaratnam pleaded guilty in federal court to two felony counts of paying half-a-million dollars in illegal kickbacks for patient referrals. Prosecutors say he and a co-defendant, who also admitted guilt, recruited homeless people on Medicare and Medi-Cal for hospitalization, even though they weren’t sick. They then billed the government health programs for unnecessary medical care.
Sabaratnam agreed to pay more than $4 million in restitution to Medicare and Medi-Cal. The 64-year-old Brentwood physician faces up to 10 years in prison when he is sentenced in June.
Tools
Friday, December 5, 2008
HHS and DOJ Health Care Fraud and Abuse Control Program
HHS and DOJ Health Care Fraud and Abuse Control Program
Annual Report For FY 2007
The Department of Health and Human Services And The Department of Justice Health Care Fraud and Abuse Control Program
Annual Report For FY 2007,
November 2008
"The Health Insurance Portability and Accountability Act of 1996 (HIPAA) established a national Health Care Fraud and Abuse Control Program (HCFAC or the Program), under the joint direction of the Attorney General and the Secretary of the Department of Health and Human Services (HHS)1, acting through the Department’s Inspector General (HHS/OIG), designed to coordinate Federal, state and local law enforcement activities with respect to health care fraud and abuse. In its eleventh year of operation, the Program’s continued success again confirms the soundness of a collaborative approach to identify and prosecute the most egregious instances of health care fraud, to prevent future fraud or abuse, and to protect program beneficiaries."
Permanent Link Topic(s): E-Government, Government Documents
Annual Report For FY 2007
The Department of Health and Human Services And The Department of Justice Health Care Fraud and Abuse Control Program
Annual Report For FY 2007,
November 2008
"The Health Insurance Portability and Accountability Act of 1996 (HIPAA) established a national Health Care Fraud and Abuse Control Program (HCFAC or the Program), under the joint direction of the Attorney General and the Secretary of the Department of Health and Human Services (HHS)1, acting through the Department’s Inspector General (HHS/OIG), designed to coordinate Federal, state and local law enforcement activities with respect to health care fraud and abuse. In its eleventh year of operation, the Program’s continued success again confirms the soundness of a collaborative approach to identify and prosecute the most egregious instances of health care fraud, to prevent future fraud or abuse, and to protect program beneficiaries."
Permanent Link Topic(s): E-Government, Government Documents
Saturday, October 4, 2008
Link NCFE to Financial and Healthcare FRAUD!
All you have to do is go to the trial currently in Colimbus Ohio, NCFE>
You can verify the link between the financial and healtcare industries.
No doubt one of the leading issues in this election is the question of health care coverage. For working Americans apart from losing their job there is no greater fear than inability to pay for their health care costs. Each year the number of working Americans who are uninsured gets closer to 50% and even for those that have some form of coverage it is often inadequate to their needs. The Democratic and Republican Plans are significantly different in their ways to address this issue. Which is better prescription for America?
First lets clarify what are the current problems?
Note enough people are currently covered by any plan.Any solution has to significantly include basically the whole of the population. We can longer have a system of “charity’ that assumes that providers and hospitals will donate to the needy. This system assumes the old concept of ability of pay based upon an individuals income is still in place. By definition for it to work requires that those who can pay more will pay higher prices to subsidize the care of the uninsured or under insured. This has created a disaster in health care because it makes it impossible to know what are the real prices in health care. How did it ever occur that private payers, Medicare, and health insurance can pay very different fees to the same provider for the same service. Most of the people who have health insurance are over the age of forty. The system will always be under capitalized unless the vast majority of young workers begin paying into system which is the major problem with a program that leaves too many not participating. For this reason the concept that Hillary Clinton recommended of “pay or play” is a sound construct.
Coverage varies widely too much between plans. Consumers cannot compare pricing of insurance plans because there is no real standard for what the term ‘insurance’ means. The reality is that none of us can ever be correct about what predicting our future medical expenses will be. Opting for a ‘cheap’ high deductible plan even for a healthy 20 year old can be a nightmare if out of the blue he or she is suddenly involved in a major automobile accident or delivers a premature baby. To call something a legal medical insurance plan means that it has to cover major conditions reasonably well within the income of the individual covered. Who is going to oversee this to prevent another crisis similar to the subprime loan fiasco?
Making health insurance job based limits the consumers options for alternatives and creates problems when there is a change in the job status.
The current system of job based insurance began during World War II as a simple way to give the public coverage who mostly worked in large war related industries. It did not envision that a majority of Americans would be working for small business or that adults may change jobs seventeen times or more in a lifetime. Labor unions played a great role in advocating the need for health care of their workers and often health care benefits become the key point of corporate-labor negotiations. But now it plays too much of role in the fight of whether labor should be unionized or not. The American auto industry has been rendered severely non-competitive by high health care costs which would be lower if they were shared in a larger risk pool than just one company or industry. McCain is right in not making health insurance job based.
The economy is weak and there is limited funds for health care. Every year our society gets older and our medical technology gets more expensive. Although health care is a necessity for a civilized nation it is not an industry that really improves the overall production of wealth. We can only expend so much of our overall budget as a nation on health care. Expense or overpriced treatments that are not proven to be clearly of value cannot be afforded. We have to mandate more complete coverage for proven effective treatment of conditions which are life threatening and minimize or exclude coverage of unproven treatment of conditions which are unlikely to benefit from such treatment. While many people cannot get enough coverage for the treatment of cancer, billions of dollars are wasted every year in operations and treatment of chronic pain conditions that are likely of no real benefit. However, one cannot be an advocate for health care without understanding that the most important single factor in determing whether health care is affordable is the health of the economy.
There are conflicting reports from recognized “think-tanks” about which plan would be best.
To evaluate the candidates’ proposals, the Commonwealth Fund Commission identified “several key principles for moving the health system toward high performance. They include:provision of equitable and comprehensive insurance for all;provision of benefits that cover essential services with appropriate financial protection;premiums, deductibles, and out-of-pocket costs are affordable relative to family income;health risks are broadly pooled;the proposals should be simple to administer, with coverage that is automatic and continuous;dislocation should be kept to a minimum—people could choose to keep the coverage they have; and financing should be adequate, fair, and shared across stakeholders.” Measured against these broad principles,they continue, Obama’s proposal for mixed private–public group insurance with a shared responsibility for financing has” greater potential to move the health care system toward high performance than does McCain’s proposal to encourage individual market coverage through the use of tax incentives and deregulation. Compared with McCain’s approach, Obama’s approach could provide more people with affordable health insurance that covers essential services, achieve greater equity in access to care, realize efficiencies and cost savings in the provision of coverage and delivery of care, and redirect incentives to improve quality. In the absence of a requirement that everyone has affordable coverage, however, the proposal is likely to fall short of achieving universal coverage.”
Robert E. Moffit, Ph.D., is Director of the Center for Health Policy Studies at The Heritage Foundation says the Obama Plan is “Not the Right Prescription”. He states “Proponents of government competition in a “national health insurance exchange” claim that it would enhance personal choice and health plan competition. That is highly unlikely. Rather, such a system would impose federal control over virtually every aspect of private health insurance, rendering it virtually indistinguishable from government insurance except for its direct financing. Congress would become increasingly prescriptive over benefits, the adoption of medical technology and new medical procedures, the pricing of these items, and the mechanism that plans may or may not use to manage health care risks. In other words, hardly any aspect of private health plans’ business operations would be free from government regulation and control. That is not a prescription for health care choice or competition.”
In my opinion, there is good and bad in both the McCain and Obama plans. Unfortunately, neither plan really addresses the most important issue of determining how much money will be paid for what. The medical system as it is currently structured is filled with waste and maybe some fraud. The Wall Street financial crisis may be a mouse compared to the elephant of the health care industry. Many health care insurance CEOs are actually even better paid that Wall Street executives. These days the most expensive car in the “doctor’s parking lot” does not belong to the heart surgeon but usually the hospital administrator. Even if you believe that physicians are over paid, many studies have shown that given the number of years of training and hours worked they are not, there is no doubt that nurses are severely underpaid. Yet some of the fastest growing salaries in America are those of health care executives at every level which more often than not have nothing to do with performance. Physicians must be allowed to develop appropriate standards of what care should be covered in the same manner that has resulted in the Veteran’s Hospitals going from once being thought of as substandard to now being leaders in the care of chronic conditions such as diabetes.
At the same time I agree with Dr. Moffit that making the government a competitor against insurance companies will serve no purpose.The biggest obstacle to private health care is the fact that it is appropriately a right. Mandated services to the public such as fire departments, schools, and garbage disposal must be highly regulated and overseen if they provided privately. For these types of services there is a very real issue as to whether competition is necessary or functional. Health care by definition cannot really be a “profitable” venture because it does not produce wealth it is a social good. Fostering competition in the American health care community has resulted in too many hospitals being too close together with many redundant services. Does it make sense for every doctor’s office to have its own office equipment, waiting room, and billing staff which add significantly to their overheads. False notions about competition make it very difficult for doctors to deal with insurance companies because of anti- trust laws.These types of administrative costs add trillions to the overall cost of health care and tend to make hospitals general centers of overall care but limit the possibility of creating real regional center of expertise.
Finally as Sarah Palin said in the recent Vice-Presidential debate, there is the issue of personal responsibility. As a retired physician who has practiced not only in the United States but visited in other countries I have seen that Americans are unique in demanding often unnecessary services. Injured workers go to court to ask for thousands of dollars for massage treatments that no one really feels will be of any benefit. Many chronic conditions are treated with drugs and therapy treatments which are no more effective than placebos. Obesity, smoking, alcohol abuse, and reckless behavior are more than just a drop in the bucket of overall health expenditures. Americans have to think of themselves as being members of a large extended family with only one budget that needs to be used for the good of us all and not the gluttony of one.
Go To Contempo Magazine Home Page
You can verify the link between the financial and healtcare industries.
No doubt one of the leading issues in this election is the question of health care coverage. For working Americans apart from losing their job there is no greater fear than inability to pay for their health care costs. Each year the number of working Americans who are uninsured gets closer to 50% and even for those that have some form of coverage it is often inadequate to their needs. The Democratic and Republican Plans are significantly different in their ways to address this issue. Which is better prescription for America?
First lets clarify what are the current problems?
Note enough people are currently covered by any plan.Any solution has to significantly include basically the whole of the population. We can longer have a system of “charity’ that assumes that providers and hospitals will donate to the needy. This system assumes the old concept of ability of pay based upon an individuals income is still in place. By definition for it to work requires that those who can pay more will pay higher prices to subsidize the care of the uninsured or under insured. This has created a disaster in health care because it makes it impossible to know what are the real prices in health care. How did it ever occur that private payers, Medicare, and health insurance can pay very different fees to the same provider for the same service. Most of the people who have health insurance are over the age of forty. The system will always be under capitalized unless the vast majority of young workers begin paying into system which is the major problem with a program that leaves too many not participating. For this reason the concept that Hillary Clinton recommended of “pay or play” is a sound construct.
Coverage varies widely too much between plans. Consumers cannot compare pricing of insurance plans because there is no real standard for what the term ‘insurance’ means. The reality is that none of us can ever be correct about what predicting our future medical expenses will be. Opting for a ‘cheap’ high deductible plan even for a healthy 20 year old can be a nightmare if out of the blue he or she is suddenly involved in a major automobile accident or delivers a premature baby. To call something a legal medical insurance plan means that it has to cover major conditions reasonably well within the income of the individual covered. Who is going to oversee this to prevent another crisis similar to the subprime loan fiasco?
Making health insurance job based limits the consumers options for alternatives and creates problems when there is a change in the job status.
The current system of job based insurance began during World War II as a simple way to give the public coverage who mostly worked in large war related industries. It did not envision that a majority of Americans would be working for small business or that adults may change jobs seventeen times or more in a lifetime. Labor unions played a great role in advocating the need for health care of their workers and often health care benefits become the key point of corporate-labor negotiations. But now it plays too much of role in the fight of whether labor should be unionized or not. The American auto industry has been rendered severely non-competitive by high health care costs which would be lower if they were shared in a larger risk pool than just one company or industry. McCain is right in not making health insurance job based.
The economy is weak and there is limited funds for health care. Every year our society gets older and our medical technology gets more expensive. Although health care is a necessity for a civilized nation it is not an industry that really improves the overall production of wealth. We can only expend so much of our overall budget as a nation on health care. Expense or overpriced treatments that are not proven to be clearly of value cannot be afforded. We have to mandate more complete coverage for proven effective treatment of conditions which are life threatening and minimize or exclude coverage of unproven treatment of conditions which are unlikely to benefit from such treatment. While many people cannot get enough coverage for the treatment of cancer, billions of dollars are wasted every year in operations and treatment of chronic pain conditions that are likely of no real benefit. However, one cannot be an advocate for health care without understanding that the most important single factor in determing whether health care is affordable is the health of the economy.
There are conflicting reports from recognized “think-tanks” about which plan would be best.
To evaluate the candidates’ proposals, the Commonwealth Fund Commission identified “several key principles for moving the health system toward high performance. They include:provision of equitable and comprehensive insurance for all;provision of benefits that cover essential services with appropriate financial protection;premiums, deductibles, and out-of-pocket costs are affordable relative to family income;health risks are broadly pooled;the proposals should be simple to administer, with coverage that is automatic and continuous;dislocation should be kept to a minimum—people could choose to keep the coverage they have; and financing should be adequate, fair, and shared across stakeholders.” Measured against these broad principles,they continue, Obama’s proposal for mixed private–public group insurance with a shared responsibility for financing has” greater potential to move the health care system toward high performance than does McCain’s proposal to encourage individual market coverage through the use of tax incentives and deregulation. Compared with McCain’s approach, Obama’s approach could provide more people with affordable health insurance that covers essential services, achieve greater equity in access to care, realize efficiencies and cost savings in the provision of coverage and delivery of care, and redirect incentives to improve quality. In the absence of a requirement that everyone has affordable coverage, however, the proposal is likely to fall short of achieving universal coverage.”
Robert E. Moffit, Ph.D., is Director of the Center for Health Policy Studies at The Heritage Foundation says the Obama Plan is “Not the Right Prescription”. He states “Proponents of government competition in a “national health insurance exchange” claim that it would enhance personal choice and health plan competition. That is highly unlikely. Rather, such a system would impose federal control over virtually every aspect of private health insurance, rendering it virtually indistinguishable from government insurance except for its direct financing. Congress would become increasingly prescriptive over benefits, the adoption of medical technology and new medical procedures, the pricing of these items, and the mechanism that plans may or may not use to manage health care risks. In other words, hardly any aspect of private health plans’ business operations would be free from government regulation and control. That is not a prescription for health care choice or competition.”
In my opinion, there is good and bad in both the McCain and Obama plans. Unfortunately, neither plan really addresses the most important issue of determining how much money will be paid for what. The medical system as it is currently structured is filled with waste and maybe some fraud. The Wall Street financial crisis may be a mouse compared to the elephant of the health care industry. Many health care insurance CEOs are actually even better paid that Wall Street executives. These days the most expensive car in the “doctor’s parking lot” does not belong to the heart surgeon but usually the hospital administrator. Even if you believe that physicians are over paid, many studies have shown that given the number of years of training and hours worked they are not, there is no doubt that nurses are severely underpaid. Yet some of the fastest growing salaries in America are those of health care executives at every level which more often than not have nothing to do with performance. Physicians must be allowed to develop appropriate standards of what care should be covered in the same manner that has resulted in the Veteran’s Hospitals going from once being thought of as substandard to now being leaders in the care of chronic conditions such as diabetes.
At the same time I agree with Dr. Moffit that making the government a competitor against insurance companies will serve no purpose.The biggest obstacle to private health care is the fact that it is appropriately a right. Mandated services to the public such as fire departments, schools, and garbage disposal must be highly regulated and overseen if they provided privately. For these types of services there is a very real issue as to whether competition is necessary or functional. Health care by definition cannot really be a “profitable” venture because it does not produce wealth it is a social good. Fostering competition in the American health care community has resulted in too many hospitals being too close together with many redundant services. Does it make sense for every doctor’s office to have its own office equipment, waiting room, and billing staff which add significantly to their overheads. False notions about competition make it very difficult for doctors to deal with insurance companies because of anti- trust laws.These types of administrative costs add trillions to the overall cost of health care and tend to make hospitals general centers of overall care but limit the possibility of creating real regional center of expertise.
Finally as Sarah Palin said in the recent Vice-Presidential debate, there is the issue of personal responsibility. As a retired physician who has practiced not only in the United States but visited in other countries I have seen that Americans are unique in demanding often unnecessary services. Injured workers go to court to ask for thousands of dollars for massage treatments that no one really feels will be of any benefit. Many chronic conditions are treated with drugs and therapy treatments which are no more effective than placebos. Obesity, smoking, alcohol abuse, and reckless behavior are more than just a drop in the bucket of overall health expenditures. Americans have to think of themselves as being members of a large extended family with only one budget that needs to be used for the good of us all and not the gluttony of one.
Go To Contempo Magazine Home Page
Tuesday, September 30, 2008
Drug manufacturer reaches $425 million fraud settlement
Drug manufacturer reaches $425 million fraud settlement
BY DREW SMITH
HARTFORD, Conn. (Legal Newsline) -- Cephalon, a Frazer, Pa.-based drug manufacturer, has announced a $425 million Medicaid fraud settlement for off-label drug marketing.
After a four-year investigation by federal and state authorities, the company was found to have marketed three drugs -- Actiq, Gabitril and Provigil -- for un-approved uses.
"Cephalon put profits over patients -- illegally promoting drugs at any cost to patients, and endangering public safety," Connecticut Attorney General Richard Blumenthal said in a statement.
Blumenthal's office participated in the investigation and settled a separate suit with Cephalon for $6.15 million.
"We are pleased to have these long-standing matters behind us, while preserving our ability to participate in all federal and state health care programs, thereby maintaining the access of patients in those programs to our medications," said Jerry Pappert, executive VP and general counsel for Cephalon.
Actiq is a pain medication with potency 100 times stronger than morphine. It was designed to treat cancer patients, but Cephalon was accused of marketing the drug to "virtually any physician who could treat chronic pain."
Gabitril is a drug that was meant to treat seizures but was found to actually cause seizures when prescribed off-label to patients who were not epileptic. After Cephalon's aggressive promotion, sales of the drug grew from $4.3 million in 2000 to $66.5 million in 2005.
In addition to paying the $425 million fine to federal authorities and $6.15 million to Connecticut, the company must also pay $12 million in accrued interest. Cephalon must also plead guilty to a misdemeanor violation and enter into a five-year Corporate Integrity Agreement.
http://www.legalnewsline.com/news/216160-drug-manufacturer-reaches-425-million-fraud-settlement
BY DREW SMITH
HARTFORD, Conn. (Legal Newsline) -- Cephalon, a Frazer, Pa.-based drug manufacturer, has announced a $425 million Medicaid fraud settlement for off-label drug marketing.
After a four-year investigation by federal and state authorities, the company was found to have marketed three drugs -- Actiq, Gabitril and Provigil -- for un-approved uses.
"Cephalon put profits over patients -- illegally promoting drugs at any cost to patients, and endangering public safety," Connecticut Attorney General Richard Blumenthal said in a statement.
Blumenthal's office participated in the investigation and settled a separate suit with Cephalon for $6.15 million.
"We are pleased to have these long-standing matters behind us, while preserving our ability to participate in all federal and state health care programs, thereby maintaining the access of patients in those programs to our medications," said Jerry Pappert, executive VP and general counsel for Cephalon.
Actiq is a pain medication with potency 100 times stronger than morphine. It was designed to treat cancer patients, but Cephalon was accused of marketing the drug to "virtually any physician who could treat chronic pain."
Gabitril is a drug that was meant to treat seizures but was found to actually cause seizures when prescribed off-label to patients who were not epileptic. After Cephalon's aggressive promotion, sales of the drug grew from $4.3 million in 2000 to $66.5 million in 2005.
In addition to paying the $425 million fine to federal authorities and $6.15 million to Connecticut, the company must also pay $12 million in accrued interest. Cephalon must also plead guilty to a misdemeanor violation and enter into a five-year Corporate Integrity Agreement.
http://www.legalnewsline.com/news/216160-drug-manufacturer-reaches-425-million-fraud-settlement
Sunday, September 28, 2008
Prosecutors began their investigation after several U.S. employees of Swiss-based Serono claimed fraud.
"...president of a medical device company was sentenced Wednesday to three years probation and fined $10,000 for plotting ..."
Serono and its U.S. subsidiaries agreed in October 2005 to pay $704 million to resolve civil and criminal charges.
Executive sentenced in Serono fraud case
By Jay Lindsay, Associated PressWriter09.25.2008
Categories AP Business Business & Finance conspiracy Corporate management Court Proceedings crime Drug approvals General news Government and politics health Medical equipment and supplies manufacturing Technology Weight loss technologies
Comments 0
The president of a medical device company was sentenced Wednesday to three years probation and fined $10,000 for plotting with Swiss-based Serono Laboratories to increase sales of an AIDS drug by manipulating a test for AIDS patients.
Rudolph Liedtke, president of Michigan-based RJL Sciences, pleaded guilty to conspiracy in 2005 for making and selling a software package in a device that Serono used to diagnose AIDS "wasting," an often fatal condition involving severe weight loss.
Prosecutors said the device diagnosed wasting even without weight loss so that Serono could increase sales of its drug Serostim. Demand for the drug had dropped in the late 1990s with the advent of "cocktails" of AIDS drugs that prevented wasting.
After Liedtke's cooperation with federal authorities, Serono and its U.S. subsidiaries agreed in October 2005 to pay $704 million to resolve civil and criminal charges.
On Wednesday, prosecutors asked U.S. District Judge Edward Harrington to sentence Liedtke to a prison sentence of just less than 3½ years. But Harrington refused, citing the case of Dr. Norma Muurahainen, who worked as a medical director for Serono and pleaded guilty to disseminating an adulterated device, but does not face prison time.
"(Liedtke) cooperated for three years. The other person, who in my judgment is equally culpable, did not," Harrington said. "It would have been a gross disparity to give him 41 months while the doctor walks."
Liedtke, 67, and his attorney, Robert Kalec, declined comment after the hearing. Assistant U.S. Attorney Mary Elizabeth Carmody and U.S. Attorney Michael Sullivan declined comment.
As part of the plea deal, prosecutors had originally agreed to a shorter sentence than they recommended Wednesday. But Carmody said that after Liedtke pleaded guilty in April 2005, he continued selling his company's device, which had not been approved by the Food and Drug Administration.
"Our position before the court would be different had he not continued the crime after he had pled guilty," Carmody said. "How does society tolerate, how does the court tolerate this kind of behavior? How does the court know that this defendant is not going to walk out the door and do it again? That is his history."
Kalec said he couldn't justify what his client did after his guilty plea. But he said that Liedtke's wrongdoing "paled in comparison" to others in the case, and added his company's profits were minuscule next to Serono's. He argued that without Liedtke's extensive cooperation with prosecutors, Serono would not have agreed to the huge penalty, the third-largest recovery in a health care fraud case in U.S. history.
Kalec asked Harrington to sentence Liedtke to probation, arguing that Carmody's concern that Liedtke would repeat his crime was unfounded.
"How do we know he won't go out and do it again? If he's on probation, the court continues to have a hammer over his head to ensure that he doesn't," Kalec said.
In brief comments before the court, Liedtke apologized for continuing to sell the device after his guilty plea.
"I'm just very, very sorry," he said.
Serono began marketing Serostim in 1996. But demand for the drug fell off sharply in the late 1990s after"cocktails" of AIDS drugs that made patients less susceptible to wasting hit the market. Serono then conspired with RJL Sciences to create a market for Serostim by selling a software package called SomaScan, which was used to diagnose AIDS wasting, but was not approved by the Food and Drug Administration for that use.
The cost of many of the prescriptions for Serostim, $21,000 for 12 weeks of treatment, was paid by Medicaid. Prosecutors began their investigation after several U.S. employees of Swiss-based Serono claimed fraud.
Serono paid a criminal fine of $136.9 million and civil penalties of $567 million, and pleaded guilty to federal conspiracy charges.
____
AP Legal Affairs Writer Denise Lavoie contributed to this report from Boston
Serono and its U.S. subsidiaries agreed in October 2005 to pay $704 million to resolve civil and criminal charges.
Executive sentenced in Serono fraud case
By Jay Lindsay, Associated PressWriter09.25.2008
Categories AP Business Business & Finance conspiracy Corporate management Court Proceedings crime Drug approvals General news Government and politics health Medical equipment and supplies manufacturing Technology Weight loss technologies
Comments 0
The president of a medical device company was sentenced Wednesday to three years probation and fined $10,000 for plotting with Swiss-based Serono Laboratories to increase sales of an AIDS drug by manipulating a test for AIDS patients.
Rudolph Liedtke, president of Michigan-based RJL Sciences, pleaded guilty to conspiracy in 2005 for making and selling a software package in a device that Serono used to diagnose AIDS "wasting," an often fatal condition involving severe weight loss.
Prosecutors said the device diagnosed wasting even without weight loss so that Serono could increase sales of its drug Serostim. Demand for the drug had dropped in the late 1990s with the advent of "cocktails" of AIDS drugs that prevented wasting.
After Liedtke's cooperation with federal authorities, Serono and its U.S. subsidiaries agreed in October 2005 to pay $704 million to resolve civil and criminal charges.
On Wednesday, prosecutors asked U.S. District Judge Edward Harrington to sentence Liedtke to a prison sentence of just less than 3½ years. But Harrington refused, citing the case of Dr. Norma Muurahainen, who worked as a medical director for Serono and pleaded guilty to disseminating an adulterated device, but does not face prison time.
"(Liedtke) cooperated for three years. The other person, who in my judgment is equally culpable, did not," Harrington said. "It would have been a gross disparity to give him 41 months while the doctor walks."
Liedtke, 67, and his attorney, Robert Kalec, declined comment after the hearing. Assistant U.S. Attorney Mary Elizabeth Carmody and U.S. Attorney Michael Sullivan declined comment.
As part of the plea deal, prosecutors had originally agreed to a shorter sentence than they recommended Wednesday. But Carmody said that after Liedtke pleaded guilty in April 2005, he continued selling his company's device, which had not been approved by the Food and Drug Administration.
"Our position before the court would be different had he not continued the crime after he had pled guilty," Carmody said. "How does society tolerate, how does the court tolerate this kind of behavior? How does the court know that this defendant is not going to walk out the door and do it again? That is his history."
Kalec said he couldn't justify what his client did after his guilty plea. But he said that Liedtke's wrongdoing "paled in comparison" to others in the case, and added his company's profits were minuscule next to Serono's. He argued that without Liedtke's extensive cooperation with prosecutors, Serono would not have agreed to the huge penalty, the third-largest recovery in a health care fraud case in U.S. history.
Kalec asked Harrington to sentence Liedtke to probation, arguing that Carmody's concern that Liedtke would repeat his crime was unfounded.
"How do we know he won't go out and do it again? If he's on probation, the court continues to have a hammer over his head to ensure that he doesn't," Kalec said.
In brief comments before the court, Liedtke apologized for continuing to sell the device after his guilty plea.
"I'm just very, very sorry," he said.
Serono began marketing Serostim in 1996. But demand for the drug fell off sharply in the late 1990s after"cocktails" of AIDS drugs that made patients less susceptible to wasting hit the market. Serono then conspired with RJL Sciences to create a market for Serostim by selling a software package called SomaScan, which was used to diagnose AIDS wasting, but was not approved by the Food and Drug Administration for that use.
The cost of many of the prescriptions for Serostim, $21,000 for 12 weeks of treatment, was paid by Medicaid. Prosecutors began their investigation after several U.S. employees of Swiss-based Serono claimed fraud.
Serono paid a criminal fine of $136.9 million and civil penalties of $567 million, and pleaded guilty to federal conspiracy charges.
____
AP Legal Affairs Writer Denise Lavoie contributed to this report from Boston
Friday, September 5, 2008
Banks Are Uniquely Positioned to Prevent Health Care Fraud
How about Banks assist with Health Care Fraud? Perfect example is NCFE missing the Founder and CEO and also an "Executive" James K Happ.....the person who assisted GW Bush's ex-partner Richard Rainwater in the "PONZI SCHEME" as noted by Federal Prosecutors involved in the case they would like to to reference as "an end to an era".
Not so fast.....so much more to KNOW! James K Happ....(Smoking GUN)
Banks Are Uniquely Positioned to Prevent Health Care Fraud
By Matt Squire
Bank compliance professionals are in a prime position to uncover health care fraud if they are aware of the tell-tale signs and report the related suspicious activity to law enforcement, say fraud investigators.
Health care fraud accounts for around 10 percent or $100 billion of the $1 trillion spent annually in the health care industry, according to the U.S. Government Accountability Office.
Not so fast.....so much more to KNOW! James K Happ....(Smoking GUN)
Banks Are Uniquely Positioned to Prevent Health Care Fraud
By Matt Squire
Bank compliance professionals are in a prime position to uncover health care fraud if they are aware of the tell-tale signs and report the related suspicious activity to law enforcement, say fraud investigators.
Health care fraud accounts for around 10 percent or $100 billion of the $1 trillion spent annually in the health care industry, according to the U.S. Government Accountability Office.
Friday, August 15, 2008
US Rep. Ileana Ros-Lehtinen rejects Medicare fraud remedy....
You wonder why?
"...fraud seems to be a major industry in South Florida..."
"...billions of dollars defrauded from Medicare...."
"...Ros-Lehtinen has banked $180,000 from Big Pharma and HMOs."
NOW Commect the dots to FINANCIAL & HEALTHCARE FRAUD!
JUST LOOK AT THE TRIAL, dubbed by Fed Prosecutors as Largest Private Fraud Case in the history of America:
Poulsen was president, chairman, chief executive officer and an owner of Dublin, Ohio-based NCFE, one of the largest healthcare finance companies in the United States until it filed for bankruptcy in November 2002.
After the witness tampering indictment was returned, Poulsen’s fraud trial was severed from the other NCFE defendants. Poulsen will face the fraud charges at trial scheduled to begin Oct. 1, 2008. Demmler's sentencing date has not yet been set. Both men have been in custody since their arrests.
The case is being prosecuted by Assistant U.S. Attorney Doug Squires and Trial Attorneys Leo Wise and Nathan Dimock of the Criminal Division’s Fraud Section. The case was investigated by the FBI.
Go to: http://biggerthanenron.blogspot.com
Tuesday, August 12, 2008
US Rep. Ileana Ros-Lehtinen rejects Medicare fraud remedy
The Miami Herald is outdoing itself lately with investigations. As the staff shrinks, will the good work still have a chance to continue? The answer will have telling effect on our civic culture, and on the jail population. Fewer crooks will be incarcerated if the Herald isn’t able to keep on exposing fraud.
In fact, fraud seems to be a major industry in South Florida. Look at two of our most important economic sectors:
· Real estate. Mortgage fraud on all sides has been exposed in the Herald as a reason for the steep rise of home prices a few years ago and now the drop. This was accomplished by our neighbors the bankers, mortgage brokers, borrowers and lenders. Working together and individually to get rich like good Americans or just to be housed, they came close to wrecking the whole national economy. Rampant was the word the Herald used to characterize the level of mortgage fraud.
· Health care. Now the Herald has chronicled billions of dollars defrauded from Medicare – that’s from our pockets, fellow citizens – by our neighbors, the fraudsters. This was billions annually in South Florida, not the whole country. An incredible haul. Perhaps it explains the big houses and fancy yachts in our splendid part of the land.
And what is the remedy? Congress! At least in the case of Medicare fraud. So it says on the front page of Monday’s Herald. Headline: Fraud Remedy Denied.
Headlines often are written in the passive voice without full verb forms. Let’s do a little exercise here and put this in the active voice. Congress Denied Fraud Remedy.
As the Herald’s Jay Weaver reported exhaustively, the Medicare agency tried repeatedly for more money to combat fraud, and Congress always throttled the attempt. Weaver shows fine enterprise in interviewing two local members of Congress to delve into the reasons.
Interestingly, Republican Sen. Mel Martinez is on the good side (first-termer behavior?) of this issue, and is backing legislation to stop fraud. He says $1 invested in anti-fraud measures will yield $10 in fraud-reduction, the Herald reports.
Then Weaver turns to my congresswoman, Rep. Ileana Ros-Lehtinen, FL-18, in the U.S. House since 1989, and she speaks out of both sides of her Republican mouth. Medicare needs help to fight fraud, but it’s risky for lawmakers to give money to an agency recognized for incompetence, she says:
“If you increase the money for oversight, then it looks like you’re fattening up the bureaucracy, even when it’s really for oversight and fighting fraud,” she said. “It’s a difficult choice.”
She then chose according to the ideology of small-government-is-best, and voted against it.
Perhaps it’s not ideology. Campaign donations could be another motivation. And thanks to research from the Florida Democratic Party, we have some detail on Ros-Lehtinen’s connection to Medicare fraud via past donations for her re-election.
From an FDP news release last week:
“In 1998, the largest home health care provider in South Florida was charged with bilking Medicare for more than $45 million in fake services. The company's founder had been a donor to Ileana Ros-Lehtinen's campaign for re-election to Congress.
“Congress did have the opportunity to fight back against Medicare fraud before it reached crisis proportions, but Ros-Lehtinen voted against allowing Congress to pursue its Constitutionally-mandated oversight role. In 1995, she voted for the so-called Medicare Preservation Act (HR 2421, Roll Call 731, 1995). The Act that Ros-Lehtinen voted for "crippled the efforts of law enforcement agencies to control health-care fraud abuse in the Medicare program," according to the then-inspector general of the Department of Health and Human Services.
“Even then, Ros-Lehtinen voted with the Republican Party line and against the best interest of the people of her district, a pattern that continues almost 15 years later.”
The FDP release reports that Ros-Lehtinen has banked $180,000 from Big Pharma and HMOs.
The charge:
“Ros-Lehtinen is either complicit or easily bamboozled, but any way you cut it she has no business representing South Florida in the United States Congress,” said Eric Jotkoff, FDP spokesman.
http://eyeonileana.blogspot.com/2008/08/us-rep-ileana-ros-lehtinen-rejects.html
"...fraud seems to be a major industry in South Florida..."
"...billions of dollars defrauded from Medicare...."
"...Ros-Lehtinen has banked $180,000 from Big Pharma and HMOs."
NOW Commect the dots to FINANCIAL & HEALTHCARE FRAUD!
JUST LOOK AT THE TRIAL, dubbed by Fed Prosecutors as Largest Private Fraud Case in the history of America:
Poulsen was president, chairman, chief executive officer and an owner of Dublin, Ohio-based NCFE, one of the largest healthcare finance companies in the United States until it filed for bankruptcy in November 2002.
After the witness tampering indictment was returned, Poulsen’s fraud trial was severed from the other NCFE defendants. Poulsen will face the fraud charges at trial scheduled to begin Oct. 1, 2008. Demmler's sentencing date has not yet been set. Both men have been in custody since their arrests.
The case is being prosecuted by Assistant U.S. Attorney Doug Squires and Trial Attorneys Leo Wise and Nathan Dimock of the Criminal Division’s Fraud Section. The case was investigated by the FBI.
Go to: http://biggerthanenron.blogspot.com
Tuesday, August 12, 2008
US Rep. Ileana Ros-Lehtinen rejects Medicare fraud remedy
The Miami Herald is outdoing itself lately with investigations. As the staff shrinks, will the good work still have a chance to continue? The answer will have telling effect on our civic culture, and on the jail population. Fewer crooks will be incarcerated if the Herald isn’t able to keep on exposing fraud.
In fact, fraud seems to be a major industry in South Florida. Look at two of our most important economic sectors:
· Real estate. Mortgage fraud on all sides has been exposed in the Herald as a reason for the steep rise of home prices a few years ago and now the drop. This was accomplished by our neighbors the bankers, mortgage brokers, borrowers and lenders. Working together and individually to get rich like good Americans or just to be housed, they came close to wrecking the whole national economy. Rampant was the word the Herald used to characterize the level of mortgage fraud.
· Health care. Now the Herald has chronicled billions of dollars defrauded from Medicare – that’s from our pockets, fellow citizens – by our neighbors, the fraudsters. This was billions annually in South Florida, not the whole country. An incredible haul. Perhaps it explains the big houses and fancy yachts in our splendid part of the land.
And what is the remedy? Congress! At least in the case of Medicare fraud. So it says on the front page of Monday’s Herald. Headline: Fraud Remedy Denied.
Headlines often are written in the passive voice without full verb forms. Let’s do a little exercise here and put this in the active voice. Congress Denied Fraud Remedy.
As the Herald’s Jay Weaver reported exhaustively, the Medicare agency tried repeatedly for more money to combat fraud, and Congress always throttled the attempt. Weaver shows fine enterprise in interviewing two local members of Congress to delve into the reasons.
Interestingly, Republican Sen. Mel Martinez is on the good side (first-termer behavior?) of this issue, and is backing legislation to stop fraud. He says $1 invested in anti-fraud measures will yield $10 in fraud-reduction, the Herald reports.
Then Weaver turns to my congresswoman, Rep. Ileana Ros-Lehtinen, FL-18, in the U.S. House since 1989, and she speaks out of both sides of her Republican mouth. Medicare needs help to fight fraud, but it’s risky for lawmakers to give money to an agency recognized for incompetence, she says:
“If you increase the money for oversight, then it looks like you’re fattening up the bureaucracy, even when it’s really for oversight and fighting fraud,” she said. “It’s a difficult choice.”
She then chose according to the ideology of small-government-is-best, and voted against it.
Perhaps it’s not ideology. Campaign donations could be another motivation. And thanks to research from the Florida Democratic Party, we have some detail on Ros-Lehtinen’s connection to Medicare fraud via past donations for her re-election.
From an FDP news release last week:
“In 1998, the largest home health care provider in South Florida was charged with bilking Medicare for more than $45 million in fake services. The company's founder had been a donor to Ileana Ros-Lehtinen's campaign for re-election to Congress.
“Congress did have the opportunity to fight back against Medicare fraud before it reached crisis proportions, but Ros-Lehtinen voted against allowing Congress to pursue its Constitutionally-mandated oversight role. In 1995, she voted for the so-called Medicare Preservation Act (HR 2421, Roll Call 731, 1995). The Act that Ros-Lehtinen voted for "crippled the efforts of law enforcement agencies to control health-care fraud abuse in the Medicare program," according to the then-inspector general of the Department of Health and Human Services.
“Even then, Ros-Lehtinen voted with the Republican Party line and against the best interest of the people of her district, a pattern that continues almost 15 years later.”
The FDP release reports that Ros-Lehtinen has banked $180,000 from Big Pharma and HMOs.
The charge:
“Ros-Lehtinen is either complicit or easily bamboozled, but any way you cut it she has no business representing South Florida in the United States Congress,” said Eric Jotkoff, FDP spokesman.
http://eyeonileana.blogspot.com/2008/08/us-rep-ileana-ros-lehtinen-rejects.html
Saturday, August 2, 2008
Medical Equipment Company Sentenced ...but what was the deal
AND WHERE IS THE MONEY? SHOW ME THE MONEY!
Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud
July 3, 2008
A Miami resident was sentenced to 130 months in prison for his role in schemes to defraud the Medicare program, Acting Assistant Attorney General Matthew Friedrich of the Criminal Division and U.S. Attorney R. Alexander Acosta of the Southern District of Florida has announced.
Gustavo Smith, 43, was sentenced in the U.S. District Court for the Southern District of Florida by Judge Marcia G. Cooke. In addition to the prison sentence, Judge Cooke ordered Smith to serve three years of supervised release following his release from prison, forfeit $287,000 and pay $1,988,969 in restitution to the U.S. Department of Health and Human Services (HHS).
At trial, the jury heard testimony that Smith was the owner of Medstar Services and Orthotics Fitters of Miami, two durable medical equipment (DME) companies that Smith used to submit more than $4.6 million in fraudulent claims to the Medicare program. The items billed by Medstar Services and Orthotics Fitters to the Medicare program were primarily negative pressure pumps and related wound care supplies. Medicare beneficiaries whose names and Medicare numbers Smith used to bill for these items testified at trial that they had never heard of Smith or his companies and that they never needed or received the items being billed to Medicare by Medstar and Orthotics Fitters. Doctors whose provider numbers were used by Smith to bill the Medicare program also testified that they had never heard of Smith or his companies and that they had never prescribed the items being billed by Smith’s companies.
Several of Smith’s associates testified at trial that Smith would open companies in the names of nominee owners, who would be listed as owners in official corporate documents, bank accounts and in official Medicare documents. Once Medicare made payments on the fraudulent claims submitted by Smith’s companies, Smith employed a money launderer to cash the proceeds of the fraud and transfer the cash to Smith. Witnesses also testified that Smith used the Medicare money to buy jewelry, purchase airline tickets for personal travel and make payments on his Mercedes-Benz.
In addition to the Medstar and Orthotics Fitters fraud, witnesses also testified about several other forms of health care fraud in which Smith engaged, including: brokering the purchase and sale of DME companies for the purpose of “burning Medicare,” or submitting more than a million dollars in fraudulent claims within a window of two to three weeks; accepting payments from approximately 180 DME companies in return for agreeing to be listed in official Medicare records as the DME companies’ orthotics fitter, when in reality Smith performed no services for those companies; and owning an interest in two additional medical equipment companies that were committing Medicare fraud.
Following a six-day trial, Smith was convicted on April 23, 2008, of all counts contained in a seventeen count indictment, including conspiracy to defraud the United States, to commit health care fraud, and to cause the submission of false claims; seven counts of health care fraud; seven counts of false claims; one count of conspiracy to launder the proceeds of his crimes; and money laundering. Smith was allowed by the court to remain free on bond after his conviction, with the requirement that he be placed on home confinement with electronic monitoring. On June 14, 2008, Smith violated the terms of his release and fled the country. A warrant has been issued for his arrest.
The case was prosecuted by Trial Attorneys Hank Bond Walther and John K. Neal of the Criminal Division’s Fraud Section in Washington, D.C., with the investigative assistance of the FBI and HHS, Office of Inspector General. The case was brought as part of the Medicare Fraud Strike Force, supervised by the Fraud Section of the Criminal Division and U.S. Attorney Acosta of the Southern District of Florida. From investigations opened during the period of Strike Force operations between March and October of 2007, federal prosecutors have indicted 82 cases with 142 defendants in South Florida. Collectively, these defendants billed the Medicare program for more than $492 million.
Source: DoJ
Net News Publisher for World News
Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud
July 3, 2008
A Miami resident was sentenced to 130 months in prison for his role in schemes to defraud the Medicare program, Acting Assistant Attorney General Matthew Friedrich of the Criminal Division and U.S. Attorney R. Alexander Acosta of the Southern District of Florida has announced.
Gustavo Smith, 43, was sentenced in the U.S. District Court for the Southern District of Florida by Judge Marcia G. Cooke. In addition to the prison sentence, Judge Cooke ordered Smith to serve three years of supervised release following his release from prison, forfeit $287,000 and pay $1,988,969 in restitution to the U.S. Department of Health and Human Services (HHS).
At trial, the jury heard testimony that Smith was the owner of Medstar Services and Orthotics Fitters of Miami, two durable medical equipment (DME) companies that Smith used to submit more than $4.6 million in fraudulent claims to the Medicare program. The items billed by Medstar Services and Orthotics Fitters to the Medicare program were primarily negative pressure pumps and related wound care supplies. Medicare beneficiaries whose names and Medicare numbers Smith used to bill for these items testified at trial that they had never heard of Smith or his companies and that they never needed or received the items being billed to Medicare by Medstar and Orthotics Fitters. Doctors whose provider numbers were used by Smith to bill the Medicare program also testified that they had never heard of Smith or his companies and that they had never prescribed the items being billed by Smith’s companies.
Several of Smith’s associates testified at trial that Smith would open companies in the names of nominee owners, who would be listed as owners in official corporate documents, bank accounts and in official Medicare documents. Once Medicare made payments on the fraudulent claims submitted by Smith’s companies, Smith employed a money launderer to cash the proceeds of the fraud and transfer the cash to Smith. Witnesses also testified that Smith used the Medicare money to buy jewelry, purchase airline tickets for personal travel and make payments on his Mercedes-Benz.
In addition to the Medstar and Orthotics Fitters fraud, witnesses also testified about several other forms of health care fraud in which Smith engaged, including: brokering the purchase and sale of DME companies for the purpose of “burning Medicare,” or submitting more than a million dollars in fraudulent claims within a window of two to three weeks; accepting payments from approximately 180 DME companies in return for agreeing to be listed in official Medicare records as the DME companies’ orthotics fitter, when in reality Smith performed no services for those companies; and owning an interest in two additional medical equipment companies that were committing Medicare fraud.
Following a six-day trial, Smith was convicted on April 23, 2008, of all counts contained in a seventeen count indictment, including conspiracy to defraud the United States, to commit health care fraud, and to cause the submission of false claims; seven counts of health care fraud; seven counts of false claims; one count of conspiracy to launder the proceeds of his crimes; and money laundering. Smith was allowed by the court to remain free on bond after his conviction, with the requirement that he be placed on home confinement with electronic monitoring. On June 14, 2008, Smith violated the terms of his release and fled the country. A warrant has been issued for his arrest.
The case was prosecuted by Trial Attorneys Hank Bond Walther and John K. Neal of the Criminal Division’s Fraud Section in Washington, D.C., with the investigative assistance of the FBI and HHS, Office of Inspector General. The case was brought as part of the Medicare Fraud Strike Force, supervised by the Fraud Section of the Criminal Division and U.S. Attorney Acosta of the Southern District of Florida. From investigations opened during the period of Strike Force operations between March and October of 2007, federal prosecutors have indicted 82 cases with 142 defendants in South Florida. Collectively, these defendants billed the Medicare program for more than $492 million.
Source: DoJ
Net News Publisher for World News
Labels:
Corporate Fraud,
FRAUD,
HEALTH CARE FRAUD,
lobbyists
Thursday, July 24, 2008
$60 Million to Settle False Claims Act and they still are BILLING!!!
What is wrong with this picture?
And they are allowed to still OPERATE and BILL MEDICARE/MEDICAID!!!
As part of the $60 million settlement, Cox has entered into a Corporate Integrity Agreement with the U.S. Department of Health and Human Services (HHS) Office of Inspector General. The Corporate Integrity Agreement contains measures to ensure compliance with Medicare regulations and policies in the future.
Missouri Health Care System to Pay U.S. $60 Million to Settle False Claims Act Allegations
July 23, 2008
Lester E. Cox Medical Centers, a health care system headquartered in Springfield, Mo., has agreed to pay the United States to settle claims that it violated the False Claims Act, the Anti-Kickback Statute and the Stark Statute between 1996 and 2005, by entering into certain financial relationships with referring doctors at a local physician group and engaging in improper billing practices with respect to Medicare. Cox, a not-for-profit healthcare organization, will pay the United States $60 million to resolve these claims.
Under the Stark Statute, Medicare providers like Cox are prohibited from billing the federal health care program for referrals from doctors with whom the providers have a financial relationship, unless that relationship falls within certain exceptions. The United States contended that certain relationships between Cox and physicians ran afoul of the Anti-Kickback Statute, which prohibits offering inducements to providers in return for patient referrals, and the Stark statute. Additional claims being resolved concern Cox’s inclusion of non-reimbursable costs on its Medicare cost reports and improper billings for services provided to dialysis patients.
“The Justice Department is committed to ensuring that the best interests of federal health care program patients are not compromised by unlawful payments to physicians,” said Gregory G. Katsas, Assistant Attorney General for the Justice Department’s Civil Division. “The resolution of this matter resulted in a significant recovery for taxpayers, and it exemplifies our dedication to vigorous enforcement of the Stark and Anti-Kickback Statutes.”
As part of the $60 million settlement, Cox has entered into a Corporate Integrity Agreement with the U.S. Department of Health and Human Services (HHS) Office of Inspector General. The Corporate Integrity Agreement contains measures to ensure compliance with Medicare regulations and policies in the future.
“Today’s settlement furthers both our commitment to protecting patients from improper billing practices and the continued ability of Cox to provide quality medical care in Springfield and the Ozarks,” said John F. Wood, U.S. Attorney in Kansas City, Mo. “I am pleased that we were able to resolve this matter without litigation.”
The settlement with Cox was the result of a coordinated effort by the Commercial Litigation Branch of the Justice Department’s Civil Division; the U.S. Attorney’s Office for the Western District of Missouri; HHS’ Office of Inspector General, Office of Counsel to the Inspector General, and Office of Audit Services; and the FBI.
Source: DoJ
And they are allowed to still OPERATE and BILL MEDICARE/MEDICAID!!!
As part of the $60 million settlement, Cox has entered into a Corporate Integrity Agreement with the U.S. Department of Health and Human Services (HHS) Office of Inspector General. The Corporate Integrity Agreement contains measures to ensure compliance with Medicare regulations and policies in the future.
Missouri Health Care System to Pay U.S. $60 Million to Settle False Claims Act Allegations
July 23, 2008
Lester E. Cox Medical Centers, a health care system headquartered in Springfield, Mo., has agreed to pay the United States to settle claims that it violated the False Claims Act, the Anti-Kickback Statute and the Stark Statute between 1996 and 2005, by entering into certain financial relationships with referring doctors at a local physician group and engaging in improper billing practices with respect to Medicare. Cox, a not-for-profit healthcare organization, will pay the United States $60 million to resolve these claims.
Under the Stark Statute, Medicare providers like Cox are prohibited from billing the federal health care program for referrals from doctors with whom the providers have a financial relationship, unless that relationship falls within certain exceptions. The United States contended that certain relationships between Cox and physicians ran afoul of the Anti-Kickback Statute, which prohibits offering inducements to providers in return for patient referrals, and the Stark statute. Additional claims being resolved concern Cox’s inclusion of non-reimbursable costs on its Medicare cost reports and improper billings for services provided to dialysis patients.
“The Justice Department is committed to ensuring that the best interests of federal health care program patients are not compromised by unlawful payments to physicians,” said Gregory G. Katsas, Assistant Attorney General for the Justice Department’s Civil Division. “The resolution of this matter resulted in a significant recovery for taxpayers, and it exemplifies our dedication to vigorous enforcement of the Stark and Anti-Kickback Statutes.”
As part of the $60 million settlement, Cox has entered into a Corporate Integrity Agreement with the U.S. Department of Health and Human Services (HHS) Office of Inspector General. The Corporate Integrity Agreement contains measures to ensure compliance with Medicare regulations and policies in the future.
“Today’s settlement furthers both our commitment to protecting patients from improper billing practices and the continued ability of Cox to provide quality medical care in Springfield and the Ozarks,” said John F. Wood, U.S. Attorney in Kansas City, Mo. “I am pleased that we were able to resolve this matter without litigation.”
The settlement with Cox was the result of a coordinated effort by the Commercial Litigation Branch of the Justice Department’s Civil Division; the U.S. Attorney’s Office for the Western District of Missouri; HHS’ Office of Inspector General, Office of Counsel to the Inspector General, and Office of Audit Services; and the FBI.
Source: DoJ
Tuesday, July 15, 2008
Since Poulsen's trial is now set to begin Oct. 1, it pushes the trial of James K. Happ, another former National Century executive....
Now why is this delay for Happ occurring? After the NOVEMBER election of course. Does any reporter really know where Happ is form or what his job at NCFE really was? If so, no one has yet to connect the dot!
Who does Happ really know? (Hint: Bush Connection)
The former CEO of National Century Financial Enterprises Inc. has successfully put off his trial on fraud-related charges by two months.
A federal judge ruled Friday that Lance Poulsen, the leader of the Dublin-based health-care financing company before it collapsed in 2002, will begin facing charges of securities fraud and conspiracy on Oct. 1 instead of Aug. 4. U.S. District Court Judge Algenon Marbley granted Poulsen's July 7 continuance request after Poulsen's attorneys argued they needed more time to review 40 boxes of documents the government is scheduled to make available between now and August.
"A two-month continuance will ensure that Poulsen has the time to obtain and review the documents that he plausibly claims are central to his theories of defense," Marbley wrote in his July 11 order.
Since Poulsen's trial is now set to begin Oct. 1, it pushes the trial of James K. Happ, another former National Century executive, to Dec. 1. Poulsen and Happ have both pleaded not guilty.
Poulsen, 65, co-founded National Century in 1991, building it into a major health-care financing company. It specialized in buying receivables from medical providers at a discount, which gave the health-care businesses the quick cash they needed. The receivables were then packaged as asset-backed bonds and sold to investors.
But National Century fell into Chapter 11 bankruptcy six years ago. The Justice Department alleged Poulsen and other executives ran a sophisticated Ponzi scheme that bilked investors out of nearly $2 billion. Poulsen pleaded not guilty to charges of conspiracy, securities fraud, wire fraud, money laundering conspiracy and concealment of money laundering.
Five other former National Century executives were found guilty in March of running a multiyear securities fraud at National Century. Poulsen was scheduled to go on trial with them, but his day in court on those charges was delayed because the government also accused him of trying to tamper with a witness.
Shortly after the March convictions of the five executives, Poulsen stood trial on the witness tampering charges. A jury found him and an associate, Karl Demmler, guilty of trying to bribe a government witness who is planning to testify against Poulsen in his securities fraud trial.
Who does Happ really know? (Hint: Bush Connection)
The former CEO of National Century Financial Enterprises Inc. has successfully put off his trial on fraud-related charges by two months.
A federal judge ruled Friday that Lance Poulsen, the leader of the Dublin-based health-care financing company before it collapsed in 2002, will begin facing charges of securities fraud and conspiracy on Oct. 1 instead of Aug. 4. U.S. District Court Judge Algenon Marbley granted Poulsen's July 7 continuance request after Poulsen's attorneys argued they needed more time to review 40 boxes of documents the government is scheduled to make available between now and August.
"A two-month continuance will ensure that Poulsen has the time to obtain and review the documents that he plausibly claims are central to his theories of defense," Marbley wrote in his July 11 order.
Since Poulsen's trial is now set to begin Oct. 1, it pushes the trial of James K. Happ, another former National Century executive, to Dec. 1. Poulsen and Happ have both pleaded not guilty.
Poulsen, 65, co-founded National Century in 1991, building it into a major health-care financing company. It specialized in buying receivables from medical providers at a discount, which gave the health-care businesses the quick cash they needed. The receivables were then packaged as asset-backed bonds and sold to investors.
But National Century fell into Chapter 11 bankruptcy six years ago. The Justice Department alleged Poulsen and other executives ran a sophisticated Ponzi scheme that bilked investors out of nearly $2 billion. Poulsen pleaded not guilty to charges of conspiracy, securities fraud, wire fraud, money laundering conspiracy and concealment of money laundering.
Five other former National Century executives were found guilty in March of running a multiyear securities fraud at National Century. Poulsen was scheduled to go on trial with them, but his day in court on those charges was delayed because the government also accused him of trying to tamper with a witness.
Shortly after the March convictions of the five executives, Poulsen stood trial on the witness tampering charges. A jury found him and an associate, Karl Demmler, guilty of trying to bribe a government witness who is planning to testify against Poulsen in his securities fraud trial.
Saturday, July 5, 2008
How would you expose the FRAUD ?
Before you read this , answer the question: How would one EXPOSE the FRAUD that is so EVIDENT in our HEALTH CARE SYSTEM?
The Dark Side of Whistleblowing
Neil Weinberg, 03.14.05
The government makes whistleblowers filthy rich for ferreting out fraud on the job.
Douglas Durand is the paragon of a corporate whistleblower. Shortly after stepping in as vice president of sales at TAP Pharmaceutical Products in early 1995, he began to suspect the company was conspiring with doctors to overcharge the federal government’s Medicare program by tens of millions of dollars. But instead of trying to fix the problem, he spent seven months gathering evidence of supposed fraud. Then he quit in 1996 and filed a secret lawsuit against TAP. One motive: If he could prove the company was dirty, he would share a nice chunk of any money TAP paid back to the feds.
He spent eight years helping the government build its own case against the company, visiting prosecutors in four states and testifying before a grand jury in Boston. He compiled a list of alleged TAP conspirators and then called these former colleagues while the FBI listened in. Moreover, Durand later filed suit making similar allegations against a TAP rival, the former Zeneca Inc. The feds ultimately joined him, filing civil and criminal charges against TAP and prodding it into paying the government $885 million to settle the case–six times as much as the claimed overcharges. Douglas Durand cashed in: He received $126 million from the U.S. government. Now age 53, he retired and lives with his wife and daughter in the tony enclave of Tarpon Springs, Fla.
Yet TAP itself was never accused of submitting bogus Medicare bills; it was charged under a little-known provision that holds medical suppliers accountable if others falsely bill the government for the suppliers’ products. On Oct. 3, 2001, the day prosecutors announced the settlement, they filed criminal fraud charges accusing TAP executives of perpetrating the overbilling scheme. This “sends a very strong signal to the pharmaceutical industry,” the prosecutor in the case, Michael Sullivan, publicly declared at the time.
Then Durand’s story began to fall apart. As the trial of a dozen TAP employees played out last year, defense attorneys poked holes in Durand’s claims. Kickbacks he said TAP paid to doctors never happened. Price hikes he had accused the firm of imposing to overcharge Medicare hadn’t actually taken place. A fancy conference Durand had described as a way to bribe doctors into selling TAP’s drugs was in fact paid for by the attendees themselves.
In July a federal jury in Boston declared all the defendants not guilty. The judge then tossed out a guilty plea entered before trial by Kimberlee Chase, a TAP sales manager charged with bribing a health maintenance organization. The judge ruled that federal antikickback statutes don’t apply to HMOs, so Chase hadn’t committed a crime. Never mind that those same HMO-related allegations had been key to the government’s case against the company. It was the third time in eight years that all the employees indicted in such cases were exonerated after their employers paid big fines–Caremark coughed up $161 million and Blue Cross Blue Shield of Illinois $144 million.
So it goes in the Byzantine world of whistleblowers. In the post-Enron era, these self-appointed do-gooders are granted breathless audiences by Congress, extolled on national television and lauded by Time magazine as Persons of the Year. But some whistleblowers are motivated by greed, willing to stretch the truth for profit. That owes to the whistleblower law, adopted in 1986, that hands informants as much as a 30% cut of any money recouped by the government. It was pushed by a public-interest lawyer who then launched a practice for whistleblower cases, pocketing millions (see box, p. 92).
Since then whistleblower cases have boomed, recovering $7.9 billion from offending companies–and paying out $1.3 billion to the insiders who ratted on the wrongdoers. A whistleblower bar now spans some 200 lawyers. As word of giant awards has spread–$100 million to the two guys who blew the whistle on HCA and $32 million for a suit against Schering-Plough–the number of suits has soared. Fiscal 2003 saw 326 whistleblower suits, ten times as many as cropped up in 1986; the government gets involved in only about one-sixth of the cases, but these yield 96% of recoveries. And while the law first took aim at defense contractors and sought to protect low-level tattlers, it is now used to target fraud in health care and an array of other businesses. And at times it insulates–and enriches–higher-ups like TAP’s Durand.
In this hell-bent pursuit of jackpot justice, the prospect of a big payoff draws would-be whistleblowers “like moths to the flame,” the 4th Circuit Court of Appeals warned in 1999, when it tossed out a suit against Roche Biomedical by two employees of a merger partner who had already collected $833,000. The Bank of China has been hit with a suit for financing mislabeled mushrooms. Money manager Mario Gabelli faces a suit for allegedly putting in sham bids at auctions of wireless spectrum. An employee ratted on Odebrecht Contractors for underbidding on a federal contract, arguing it intended to raise prices later (his suit was dismissed as “fatally flawed”).
Government is often a willing accomplice, keen to look tough and cash in. It tars targets with bad press and threatens to levy fines many times the size of its own purported losses. If a company refuses to settle, the feds can move to ban it from federal business even before getting so much as an indictment. Most times companies settle, whether they are guilty or not. “It’s absolutely a form of extortion,” says attorney David Stetler, who successfully defended TAP exec Alan MacKenzie. MacKenzie last year became president of the $4 billion (sales) company.
Like whistleblowers themselves, the feds have a profit motive: They bring in $13 for each dollar spent prosecuting a case, and whistleblowers provide 52% of all U.S. government fraud recoveries, says Taxpayers Against Fraud, the whistleblower lawyers’ lobby. “It’s a tremendous return on investment,” says U.S. Attorney Sullivan, who has 13 people working on health care fraud cases. Health care now accounts for more than half of all whistleblower suits. Drugmakers have paid $2.5 billion in fines in recent years. In most instances the penalty paid was several times the losses.
Some of these winnings are funneled back into the pursuit of new cases, a nifty little move the feds began using in 1996. For several consecutive years the larger enforcement budgets have led to larger settlements, which in turn have funded still larger enforcement budgets. “It’s all done with a wink and a nod, with the bureaucrats going back to Congress and saying bigger budgets are justified by past results,” says Robert Salcido, a former federal prosecutor who defends whistleblower suits at Akin Gump Strauss Hauer & Feld.
Supporters of the whistleblower law say it is the only way to clamp down on the intractable problem of fraud in government contracts. The U.S. government spends half a trillion dollars annually on medical care, one-quarter of its budget, and fraudulent claims could total $50 billion of that sum, says the Government Accountability Office. “There can never be enough bureaucrats to discourage fraudulent use of taxpayers’ money, but knowing colleagues might squeal can be a deterrent,” says Senator Charles Grassley (R-Iowa), who pushed passage of the law.
In this for-profit justice, “financial incentives are what bring people forward,” concedes Michael Hertz, director of the Justice Department’s civil fraud section. But thereafter, he says, “a traditional fraud investigation takes place and the facts are the facts.”
Handing informants a share of the booty dates back centuries. Suits brought by citizens on a government’s behalf are known as qui tam cases, derived from the first two words of the Latin phrase meaning “whoever brings an action for the king brings it for himself.” President Lincoln introduced qui tam suits to the U.S. in 1863, signing the False Claims Act to target vendors of dud gunpowder in the Civil War.
The law languished for a century until it was revived in 1986 by Senator Grassley and John Phillips of the Center for Law in the Public Interest, the lawyer who later went into private practice to pursue whistleblower cases. They hiked a whistleblower’s cut from 10% to as much as 30% and lowered the threshold for guilt from knowingly ripping off the government to the fuzzier notion of “deliberate ignorance” or “reckless disregard” of regulations.
The whistleblower law was in full swing by the time Doug Durand landed at TAP Pharmaceutical in 1995. He grew up in Pawtucket, R.I., one of eight children, got a degree in pharmacology at the University of Rhode Island and spent 20 years selling drugs for Merck & Co.
His career there ended in a nasty dispute in 1994 in which Durand filed an Equal Employment Opportunity Commission suit against the drugmaker. He accused Merck of retaliating against him for supporting a female colleague’s claim that a Merck president had sexually harassed her. Merck paid him $255,000 to settle. Durand claimed in a related affidavit that Merck had ruined his career. Stripped of his office and duties, and exiled on paid leave, Durand applied to TAP, saying he was still a senior regional director looking to switch jobs. When he testified later before a grand jury, Durand left out all details of his Merck ouster, saying only that a headhunter had approached him.
TAP, meanwhile, was in the fight of its life. Abbott Labs and Takeda had formed the Lake Forest, Ill. company in 1977. After it developed a new monthly injection of Lupron, the first alternative to castration for advanced prostate cancer, sales jumped from $135 million in 1990 to $744 million five years later. The drug went for $400 a dose, and Medicare covered 80% of the cost.
Durand joined the company in January 1995 just as Lupron was facing fierce competition, from Zeneca’s Zoladex, a lower-cost rival. As head of sales his primary mission was to launch Prevacid, a new drug for acid reflux. But early on, he says, he grew uncomfortable with the way TAP was pushing Lupron. TAP sold it fervently, putting together a slide show on Lupron’s “return to practice” for doctors. It held seminars at fancy resorts and gave physicians TVs so they could show its promotional videos. Wags joked internally that TAP lawyers were in the “sales prevention department.”
One of Durand’s concerns involved sales reps’ failure to properly account for the free samples they gave to doctors. A precise accounting is required by federal law to prevent doctors from falsely billing Medicare for samples they received free of charge. Doctors must sign for each free dose they receive, and if they falsely bill Medicare, drugmakers can be convicted of criminal fraud.
Durand became convinced the faulty record-keeping was intentional, designed to let doctors collect extra money from Medicare. At one point he proposed linking sales reps’ bonuses to how well they accounted for free samples but was overruled, he claimed at the trial of his former colleagues. He had learned of a sales rep who had doctors sign for doses they hadn’t received–a “big problem,” he said, but didn’t recall doing anything about it. Despite Durand’s qualms, he didn’t turn to TAP’s outside counsel for advice; asked why, he testified that only two employees below the rank of vice president were allowed to do so and he was not on that short list.
In August 1995 Durand got edgier still, after people at a staff meeting discussed paying a 2% fee to Lupron doctors to cover administrative costs; federal rules allow such payments only to HMOs and other buying groups, not to individual doctors. It was tricky legal turf. “How would Doug look in [prison] stripes?” Alan MacKenzie, whom Duran outranked, joked at the meeting. Everyone else laughed, but Durand says he viewed the remark as “serious and sinister.”
Durand began looking at how to protect himself. He says he feared getting swept up in a prosecution if the feds ever stumbled upon TAP’s misdeeds. “I wanted to do the right thing,” he says. He told a former Merck colleague about the prison-stripes comment, and a month later the colleague referred him to a lawyer–Elizabeth Ainslie, a white-collar lawyer who had run the criminal fraud section in the Philadelphia U.S. Attorney’s office.
Ainslie suggested Durand begin keeping notes and collecting TAP documents for a possible whistleblower suit. Shortly afterward Durand faxed her a story headlined: “Rugby Laboratories Pays $7.5 Million to Settle Government VA Fraud Allegations; Former Employee Who Brought Qui Tam Suit Receives $1.1 Million.” He asked if this is what she had in mind; it was.
Durand began supplying the lawyer with TAP documents, letters with the company’s attorneys and memos it exchanged with its archrival, Zeneca. She showed the stuff to James Sheehan, a prosecutor in the Philadelphia office where she had worked, hoping to pique his interest in joining the case. For whistleblowers the key is to enlist the government–with its power to subpoena defendants and deprive a company of contracts before a case has been decided–as co-plaintiff.
As Ainslie wooed the feds, Durand put on a show of remaining a team player at TAP. In truth, he was the opposite. When word reached him of a California rep whose tactics were “out of line,” he left the matter to a subordinate to handle. Then he forwarded internal TAP correspondence on the matter to Ainslie.
In February 1996 Durand brought his sales managers to a golf resort in Florida and shared his vision of TAP’s future. Later that month he got his bonus for 1995 ($35,000) and quit, leaving TAP for AstraMerck. A month later he formally hired Ainslie to pursue a whistleblower case. She would cover his expenses and share in any recovery while billing defendants for her time if Durand prevailed. Three months later they filed suits against TAP and Zeneca. Like all such suits, Durand’s were filed under seal. The government was required to investigate them, and it did so, unbeknownst to the defendants.
For the ensuing five years Durand made repeated visits to U.S. attorney’s offices in Philadelphia, Boston, Chicago and Wilmington to prevail on prosecutors to join his suits. From his office at Astra he faxed a prosecutor in the Philadelphia office, Virginia Gibson Mason, calling her “Ginny” and boasting of “a productive morning!”–he had gotten the phone numbers of former subordinates to call and incriminate as the FBI listened in. The FBI made secret tape recordings of TAP employees discussing potential legal problems. In one Durand calls a former TAP colleague at his home, tells the child who answered the phone that a “friend” is calling and then lies to the TAP exec, pretending, in a bid to get the man to incriminate himself, that Durand himself had been subpoenaed; this employee wasn’t ever indicted.
Durand’s case drew the interest of prosecutors in the Boston office of the U.S. Attorney after they came across a second whistleblower, Dr. Joseph Gerstein. Gerstein oversaw drug buying at a Tufts University HMO and recently had decided to replace TAP’s Lupron with rival Zoladex. It was then, he told the feds, that TAP’s Kim Chase and a colleague offered him an “unrestricted” educational grant if he reversed his decision. Gerstein viewed it as a possible bribe. He approached TV and newspaper reporters but was ignored. Then he contacted Boston prosecutors.
“They were looking for potential cases to investigate since they have a big health care unit,” Gerstein says. He hired a lawyer and met with prosecutors in late 1996 and filed his whistleblower suit against TAP in March 1998. At the behest of federal agents, Gerstein let the FBI hide a camera in his office and wore a wire as he twice lured the TAP reps back by pretending he might reinstate Lupron. The FBI asked Gerstein to meet again to solicit a personal bribe. Queasy about the ethics, he staged the meeting but refused to come right out and ask for a kickback.
In April 2001, five years after Durand filed his suit, the Boston U.S. Attorney’s office joined it (”intervened”). Durand’s lawyer, Ainslie, drafted a motion to dismiss Gerstein’s suit, and his claim to part of the recovery, on the grounds that her client had filed first. The whistleblowers settled their spat, with Gerstein accepting a 3% cut of whatever the government recovered and Durand skimming a 14% share.
TAP denied the charges and argued that its sample program, educational grants and other efforts were entirely legal tactics common to many drugmakers. It was a losing hand. The feds had two highly motivated whistleblowers and had collected 500 boxes of documents. TAP pleaded guilty in October 2001 to what the government said was a nationwide conspiracy that included encouraging doctors to illegally bill for free samples, bribing them to get them to prescribe Lupron and reporting bogus wholesale prices to dupe Medicare into overpaying. It agreed to pay $885 million in restitution, fines and interest.
TAP has agreed to pay $150 million to settle a private suit brought by consumers, insurers and health benefit planners related to the charges, boosting its penalties past $1 billion. The government wrangled $355 million from AstraZeneca (formerly Zeneca) in 2003. Durand had never worked at Zeneca but says he sued the firm at the recommendation of Philadelphia Assistant U.S. Attorney James Sheehan, a former colleague of his attorney.
The carefully crafted deal let TAP remain a Medicare provider. The firm pleaded guilty to criminal charges of violating the Prescription Drug Marketing Act and was allowed to stay in business. Four doctors pleaded guilty to illegal billing. The day the settlement was finalized, H. Thomas Watkins, TAP’s president at the time, conceded it had provided Lupron samples to a number of doctors who illegally billed Medicare. But he added that “We fundamentally disagree with the government’s claims regarding TAP’s pricing and reimbursement policies.” TAP had agreed to pay the big fine, he added, only because the government had threatened to end federal reimbursements for Lupron, worth half a billion dollars a year.
That enraged William Young, the chief U.S. District Court judge in Boston who had approved the settlement. Young forbade TAP to make further claims of innocence. “I don’t want some p.r. flack saying this is all just a big misunderstanding,” he said.
When the separate trial of TAP employees unfolded last summer, the judge in that case, Douglas Woodlock, rejected the claims of whistleblower Gerstein wholesale. Durand testified and “had the crap beaten out of me” during a week of cross-examination, he says. His original suit claimed TAP had paid doctors 2% kickbacks, but only one customer got the fees and they were legit: Tri-State Urology, a buying group, had a legal safe harbor to receive the fees. Durand says TAP intended to kick money back to others.
He also wrongly told Chicago prosecutors that TAP fully accounted for only half of the free samples it handed out; in fact, it accounted for a far higher portion. He inaccurately testified that a meeting in Nevis, West Indies was a free junket for doctors dubbed “TAP into the Future.” In fact, it was titled “A Commitment to Urology: Therapeutic Innovations in BPH and Prostate Cancer.” Doctors paid their own way and earned educational credits.
“If you fixed the problems, do you think it would have helped your lawsuit?” Durand was asked at trial. His reply: “If I was allowed to fix the problems I was trying to fix, yes, the lawsuit would not have probably ever happened.”
By the time the legal holes, logical leaps and inaccuracies in the case were revealed in the criminal trial last year, TAP had been shaken down. Durand picked up $79 million for his TAP case and $47 million for suing AstraZeneca, and his lawyer, Ainslie, landed $13.5 million. Gerstein shared $16 million with Tufts, and his lawyer got an undisclosed sum, plus fees and expenses.
Durand appeared with a raft of other whistleblowers on Oprah Winfrey’s TV talk show in August 2002, regaling viewers with tales of his heroics. “Financially, I lost a lot,” he solemnly told his popular TV host. The show made only fleeting reference to the most interesting part–that ten months earlier he had received almost $80 million of his whistleblower windfall.
TAP may have deserved to get smacked down by prosecutors, and Durand may have deserved a reward for helping deliver it. But in other areas the government caps whistleblowers’ rewards at sane levels–$250,000 in customs cases and $1.6 million in those involving bank fraud. It’s an odd law that makes whistleblowers centimillionaires for reporting on bad behavior after silently watching it take place under their noses.
Sidebars
The Enforcer
Envy Engines
The Dark Side of Whistleblowing
Neil Weinberg, 03.14.05
The government makes whistleblowers filthy rich for ferreting out fraud on the job.
Douglas Durand is the paragon of a corporate whistleblower. Shortly after stepping in as vice president of sales at TAP Pharmaceutical Products in early 1995, he began to suspect the company was conspiring with doctors to overcharge the federal government’s Medicare program by tens of millions of dollars. But instead of trying to fix the problem, he spent seven months gathering evidence of supposed fraud. Then he quit in 1996 and filed a secret lawsuit against TAP. One motive: If he could prove the company was dirty, he would share a nice chunk of any money TAP paid back to the feds.
He spent eight years helping the government build its own case against the company, visiting prosecutors in four states and testifying before a grand jury in Boston. He compiled a list of alleged TAP conspirators and then called these former colleagues while the FBI listened in. Moreover, Durand later filed suit making similar allegations against a TAP rival, the former Zeneca Inc. The feds ultimately joined him, filing civil and criminal charges against TAP and prodding it into paying the government $885 million to settle the case–six times as much as the claimed overcharges. Douglas Durand cashed in: He received $126 million from the U.S. government. Now age 53, he retired and lives with his wife and daughter in the tony enclave of Tarpon Springs, Fla.
Yet TAP itself was never accused of submitting bogus Medicare bills; it was charged under a little-known provision that holds medical suppliers accountable if others falsely bill the government for the suppliers’ products. On Oct. 3, 2001, the day prosecutors announced the settlement, they filed criminal fraud charges accusing TAP executives of perpetrating the overbilling scheme. This “sends a very strong signal to the pharmaceutical industry,” the prosecutor in the case, Michael Sullivan, publicly declared at the time.
Then Durand’s story began to fall apart. As the trial of a dozen TAP employees played out last year, defense attorneys poked holes in Durand’s claims. Kickbacks he said TAP paid to doctors never happened. Price hikes he had accused the firm of imposing to overcharge Medicare hadn’t actually taken place. A fancy conference Durand had described as a way to bribe doctors into selling TAP’s drugs was in fact paid for by the attendees themselves.
In July a federal jury in Boston declared all the defendants not guilty. The judge then tossed out a guilty plea entered before trial by Kimberlee Chase, a TAP sales manager charged with bribing a health maintenance organization. The judge ruled that federal antikickback statutes don’t apply to HMOs, so Chase hadn’t committed a crime. Never mind that those same HMO-related allegations had been key to the government’s case against the company. It was the third time in eight years that all the employees indicted in such cases were exonerated after their employers paid big fines–Caremark coughed up $161 million and Blue Cross Blue Shield of Illinois $144 million.
So it goes in the Byzantine world of whistleblowers. In the post-Enron era, these self-appointed do-gooders are granted breathless audiences by Congress, extolled on national television and lauded by Time magazine as Persons of the Year. But some whistleblowers are motivated by greed, willing to stretch the truth for profit. That owes to the whistleblower law, adopted in 1986, that hands informants as much as a 30% cut of any money recouped by the government. It was pushed by a public-interest lawyer who then launched a practice for whistleblower cases, pocketing millions (see box, p. 92).
Since then whistleblower cases have boomed, recovering $7.9 billion from offending companies–and paying out $1.3 billion to the insiders who ratted on the wrongdoers. A whistleblower bar now spans some 200 lawyers. As word of giant awards has spread–$100 million to the two guys who blew the whistle on HCA and $32 million for a suit against Schering-Plough–the number of suits has soared. Fiscal 2003 saw 326 whistleblower suits, ten times as many as cropped up in 1986; the government gets involved in only about one-sixth of the cases, but these yield 96% of recoveries. And while the law first took aim at defense contractors and sought to protect low-level tattlers, it is now used to target fraud in health care and an array of other businesses. And at times it insulates–and enriches–higher-ups like TAP’s Durand.
In this hell-bent pursuit of jackpot justice, the prospect of a big payoff draws would-be whistleblowers “like moths to the flame,” the 4th Circuit Court of Appeals warned in 1999, when it tossed out a suit against Roche Biomedical by two employees of a merger partner who had already collected $833,000. The Bank of China has been hit with a suit for financing mislabeled mushrooms. Money manager Mario Gabelli faces a suit for allegedly putting in sham bids at auctions of wireless spectrum. An employee ratted on Odebrecht Contractors for underbidding on a federal contract, arguing it intended to raise prices later (his suit was dismissed as “fatally flawed”).
Government is often a willing accomplice, keen to look tough and cash in. It tars targets with bad press and threatens to levy fines many times the size of its own purported losses. If a company refuses to settle, the feds can move to ban it from federal business even before getting so much as an indictment. Most times companies settle, whether they are guilty or not. “It’s absolutely a form of extortion,” says attorney David Stetler, who successfully defended TAP exec Alan MacKenzie. MacKenzie last year became president of the $4 billion (sales) company.
Like whistleblowers themselves, the feds have a profit motive: They bring in $13 for each dollar spent prosecuting a case, and whistleblowers provide 52% of all U.S. government fraud recoveries, says Taxpayers Against Fraud, the whistleblower lawyers’ lobby. “It’s a tremendous return on investment,” says U.S. Attorney Sullivan, who has 13 people working on health care fraud cases. Health care now accounts for more than half of all whistleblower suits. Drugmakers have paid $2.5 billion in fines in recent years. In most instances the penalty paid was several times the losses.
Some of these winnings are funneled back into the pursuit of new cases, a nifty little move the feds began using in 1996. For several consecutive years the larger enforcement budgets have led to larger settlements, which in turn have funded still larger enforcement budgets. “It’s all done with a wink and a nod, with the bureaucrats going back to Congress and saying bigger budgets are justified by past results,” says Robert Salcido, a former federal prosecutor who defends whistleblower suits at Akin Gump Strauss Hauer & Feld.
Supporters of the whistleblower law say it is the only way to clamp down on the intractable problem of fraud in government contracts. The U.S. government spends half a trillion dollars annually on medical care, one-quarter of its budget, and fraudulent claims could total $50 billion of that sum, says the Government Accountability Office. “There can never be enough bureaucrats to discourage fraudulent use of taxpayers’ money, but knowing colleagues might squeal can be a deterrent,” says Senator Charles Grassley (R-Iowa), who pushed passage of the law.
In this for-profit justice, “financial incentives are what bring people forward,” concedes Michael Hertz, director of the Justice Department’s civil fraud section. But thereafter, he says, “a traditional fraud investigation takes place and the facts are the facts.”
Handing informants a share of the booty dates back centuries. Suits brought by citizens on a government’s behalf are known as qui tam cases, derived from the first two words of the Latin phrase meaning “whoever brings an action for the king brings it for himself.” President Lincoln introduced qui tam suits to the U.S. in 1863, signing the False Claims Act to target vendors of dud gunpowder in the Civil War.
The law languished for a century until it was revived in 1986 by Senator Grassley and John Phillips of the Center for Law in the Public Interest, the lawyer who later went into private practice to pursue whistleblower cases. They hiked a whistleblower’s cut from 10% to as much as 30% and lowered the threshold for guilt from knowingly ripping off the government to the fuzzier notion of “deliberate ignorance” or “reckless disregard” of regulations.
The whistleblower law was in full swing by the time Doug Durand landed at TAP Pharmaceutical in 1995. He grew up in Pawtucket, R.I., one of eight children, got a degree in pharmacology at the University of Rhode Island and spent 20 years selling drugs for Merck & Co.
His career there ended in a nasty dispute in 1994 in which Durand filed an Equal Employment Opportunity Commission suit against the drugmaker. He accused Merck of retaliating against him for supporting a female colleague’s claim that a Merck president had sexually harassed her. Merck paid him $255,000 to settle. Durand claimed in a related affidavit that Merck had ruined his career. Stripped of his office and duties, and exiled on paid leave, Durand applied to TAP, saying he was still a senior regional director looking to switch jobs. When he testified later before a grand jury, Durand left out all details of his Merck ouster, saying only that a headhunter had approached him.
TAP, meanwhile, was in the fight of its life. Abbott Labs and Takeda had formed the Lake Forest, Ill. company in 1977. After it developed a new monthly injection of Lupron, the first alternative to castration for advanced prostate cancer, sales jumped from $135 million in 1990 to $744 million five years later. The drug went for $400 a dose, and Medicare covered 80% of the cost.
Durand joined the company in January 1995 just as Lupron was facing fierce competition, from Zeneca’s Zoladex, a lower-cost rival. As head of sales his primary mission was to launch Prevacid, a new drug for acid reflux. But early on, he says, he grew uncomfortable with the way TAP was pushing Lupron. TAP sold it fervently, putting together a slide show on Lupron’s “return to practice” for doctors. It held seminars at fancy resorts and gave physicians TVs so they could show its promotional videos. Wags joked internally that TAP lawyers were in the “sales prevention department.”
One of Durand’s concerns involved sales reps’ failure to properly account for the free samples they gave to doctors. A precise accounting is required by federal law to prevent doctors from falsely billing Medicare for samples they received free of charge. Doctors must sign for each free dose they receive, and if they falsely bill Medicare, drugmakers can be convicted of criminal fraud.
Durand became convinced the faulty record-keeping was intentional, designed to let doctors collect extra money from Medicare. At one point he proposed linking sales reps’ bonuses to how well they accounted for free samples but was overruled, he claimed at the trial of his former colleagues. He had learned of a sales rep who had doctors sign for doses they hadn’t received–a “big problem,” he said, but didn’t recall doing anything about it. Despite Durand’s qualms, he didn’t turn to TAP’s outside counsel for advice; asked why, he testified that only two employees below the rank of vice president were allowed to do so and he was not on that short list.
In August 1995 Durand got edgier still, after people at a staff meeting discussed paying a 2% fee to Lupron doctors to cover administrative costs; federal rules allow such payments only to HMOs and other buying groups, not to individual doctors. It was tricky legal turf. “How would Doug look in [prison] stripes?” Alan MacKenzie, whom Duran outranked, joked at the meeting. Everyone else laughed, but Durand says he viewed the remark as “serious and sinister.”
Durand began looking at how to protect himself. He says he feared getting swept up in a prosecution if the feds ever stumbled upon TAP’s misdeeds. “I wanted to do the right thing,” he says. He told a former Merck colleague about the prison-stripes comment, and a month later the colleague referred him to a lawyer–Elizabeth Ainslie, a white-collar lawyer who had run the criminal fraud section in the Philadelphia U.S. Attorney’s office.
Ainslie suggested Durand begin keeping notes and collecting TAP documents for a possible whistleblower suit. Shortly afterward Durand faxed her a story headlined: “Rugby Laboratories Pays $7.5 Million to Settle Government VA Fraud Allegations; Former Employee Who Brought Qui Tam Suit Receives $1.1 Million.” He asked if this is what she had in mind; it was.
Durand began supplying the lawyer with TAP documents, letters with the company’s attorneys and memos it exchanged with its archrival, Zeneca. She showed the stuff to James Sheehan, a prosecutor in the Philadelphia office where she had worked, hoping to pique his interest in joining the case. For whistleblowers the key is to enlist the government–with its power to subpoena defendants and deprive a company of contracts before a case has been decided–as co-plaintiff.
As Ainslie wooed the feds, Durand put on a show of remaining a team player at TAP. In truth, he was the opposite. When word reached him of a California rep whose tactics were “out of line,” he left the matter to a subordinate to handle. Then he forwarded internal TAP correspondence on the matter to Ainslie.
In February 1996 Durand brought his sales managers to a golf resort in Florida and shared his vision of TAP’s future. Later that month he got his bonus for 1995 ($35,000) and quit, leaving TAP for AstraMerck. A month later he formally hired Ainslie to pursue a whistleblower case. She would cover his expenses and share in any recovery while billing defendants for her time if Durand prevailed. Three months later they filed suits against TAP and Zeneca. Like all such suits, Durand’s were filed under seal. The government was required to investigate them, and it did so, unbeknownst to the defendants.
For the ensuing five years Durand made repeated visits to U.S. attorney’s offices in Philadelphia, Boston, Chicago and Wilmington to prevail on prosecutors to join his suits. From his office at Astra he faxed a prosecutor in the Philadelphia office, Virginia Gibson Mason, calling her “Ginny” and boasting of “a productive morning!”–he had gotten the phone numbers of former subordinates to call and incriminate as the FBI listened in. The FBI made secret tape recordings of TAP employees discussing potential legal problems. In one Durand calls a former TAP colleague at his home, tells the child who answered the phone that a “friend” is calling and then lies to the TAP exec, pretending, in a bid to get the man to incriminate himself, that Durand himself had been subpoenaed; this employee wasn’t ever indicted.
Durand’s case drew the interest of prosecutors in the Boston office of the U.S. Attorney after they came across a second whistleblower, Dr. Joseph Gerstein. Gerstein oversaw drug buying at a Tufts University HMO and recently had decided to replace TAP’s Lupron with rival Zoladex. It was then, he told the feds, that TAP’s Kim Chase and a colleague offered him an “unrestricted” educational grant if he reversed his decision. Gerstein viewed it as a possible bribe. He approached TV and newspaper reporters but was ignored. Then he contacted Boston prosecutors.
“They were looking for potential cases to investigate since they have a big health care unit,” Gerstein says. He hired a lawyer and met with prosecutors in late 1996 and filed his whistleblower suit against TAP in March 1998. At the behest of federal agents, Gerstein let the FBI hide a camera in his office and wore a wire as he twice lured the TAP reps back by pretending he might reinstate Lupron. The FBI asked Gerstein to meet again to solicit a personal bribe. Queasy about the ethics, he staged the meeting but refused to come right out and ask for a kickback.
In April 2001, five years after Durand filed his suit, the Boston U.S. Attorney’s office joined it (”intervened”). Durand’s lawyer, Ainslie, drafted a motion to dismiss Gerstein’s suit, and his claim to part of the recovery, on the grounds that her client had filed first. The whistleblowers settled their spat, with Gerstein accepting a 3% cut of whatever the government recovered and Durand skimming a 14% share.
TAP denied the charges and argued that its sample program, educational grants and other efforts were entirely legal tactics common to many drugmakers. It was a losing hand. The feds had two highly motivated whistleblowers and had collected 500 boxes of documents. TAP pleaded guilty in October 2001 to what the government said was a nationwide conspiracy that included encouraging doctors to illegally bill for free samples, bribing them to get them to prescribe Lupron and reporting bogus wholesale prices to dupe Medicare into overpaying. It agreed to pay $885 million in restitution, fines and interest.
TAP has agreed to pay $150 million to settle a private suit brought by consumers, insurers and health benefit planners related to the charges, boosting its penalties past $1 billion. The government wrangled $355 million from AstraZeneca (formerly Zeneca) in 2003. Durand had never worked at Zeneca but says he sued the firm at the recommendation of Philadelphia Assistant U.S. Attorney James Sheehan, a former colleague of his attorney.
The carefully crafted deal let TAP remain a Medicare provider. The firm pleaded guilty to criminal charges of violating the Prescription Drug Marketing Act and was allowed to stay in business. Four doctors pleaded guilty to illegal billing. The day the settlement was finalized, H. Thomas Watkins, TAP’s president at the time, conceded it had provided Lupron samples to a number of doctors who illegally billed Medicare. But he added that “We fundamentally disagree with the government’s claims regarding TAP’s pricing and reimbursement policies.” TAP had agreed to pay the big fine, he added, only because the government had threatened to end federal reimbursements for Lupron, worth half a billion dollars a year.
That enraged William Young, the chief U.S. District Court judge in Boston who had approved the settlement. Young forbade TAP to make further claims of innocence. “I don’t want some p.r. flack saying this is all just a big misunderstanding,” he said.
When the separate trial of TAP employees unfolded last summer, the judge in that case, Douglas Woodlock, rejected the claims of whistleblower Gerstein wholesale. Durand testified and “had the crap beaten out of me” during a week of cross-examination, he says. His original suit claimed TAP had paid doctors 2% kickbacks, but only one customer got the fees and they were legit: Tri-State Urology, a buying group, had a legal safe harbor to receive the fees. Durand says TAP intended to kick money back to others.
He also wrongly told Chicago prosecutors that TAP fully accounted for only half of the free samples it handed out; in fact, it accounted for a far higher portion. He inaccurately testified that a meeting in Nevis, West Indies was a free junket for doctors dubbed “TAP into the Future.” In fact, it was titled “A Commitment to Urology: Therapeutic Innovations in BPH and Prostate Cancer.” Doctors paid their own way and earned educational credits.
“If you fixed the problems, do you think it would have helped your lawsuit?” Durand was asked at trial. His reply: “If I was allowed to fix the problems I was trying to fix, yes, the lawsuit would not have probably ever happened.”
By the time the legal holes, logical leaps and inaccuracies in the case were revealed in the criminal trial last year, TAP had been shaken down. Durand picked up $79 million for his TAP case and $47 million for suing AstraZeneca, and his lawyer, Ainslie, landed $13.5 million. Gerstein shared $16 million with Tufts, and his lawyer got an undisclosed sum, plus fees and expenses.
Durand appeared with a raft of other whistleblowers on Oprah Winfrey’s TV talk show in August 2002, regaling viewers with tales of his heroics. “Financially, I lost a lot,” he solemnly told his popular TV host. The show made only fleeting reference to the most interesting part–that ten months earlier he had received almost $80 million of his whistleblower windfall.
TAP may have deserved to get smacked down by prosecutors, and Durand may have deserved a reward for helping deliver it. But in other areas the government caps whistleblowers’ rewards at sane levels–$250,000 in customs cases and $1.6 million in those involving bank fraud. It’s an odd law that makes whistleblowers centimillionaires for reporting on bad behavior after silently watching it take place under their noses.
Sidebars
The Enforcer
Envy Engines
Tuesday, May 27, 2008
Open letter to Texas newspapers about peak oil: 'Why aren’t you listening?'
by Jeffrey J. Brown
April 2, 2006
Mr. Wesley R. Turner, President & Publisher
Fort Worth Star Telegram
Mr. James H. Moroney , III, Publisher & CEO
The Dallas Morning News
Subject: What Are Two Texas Billionaires,
Richard Rainwater & T. Boone Pickens,
Saying About Peak Oil & Why Aren’t You Listening?
Gentlemen:
I realize that I don’t have to introduce Richard Rainwater and Boone Pickens to you two gentlemen, but for the benefit of those who may not be familiar with Messrs. Rainwater and Pickens, following are brief introductions.
Richard Rainwater is the Texas based businessman who was chiefly responsible for turning the Bass Family’s inheritance of $50 into a $5 billion dollar fortune. Mr. Rainwater was therefore indirectly responsible for the remarkable urban renaissance of downtown Fort Worth, as a result of the Bass family’s massive investments. Mr. Rainwater also had a material role in George W. Bush’s selection as Managing Partner of the Texas Rangers Baseball Team, which launched Mr. Bush on his way to the Governor’s Mansion and then to the White House.
Mr. Pickens, now based in Dallas, has had a long and storied career in the oil and gas industry. Like most Texas oilmen, Mr. Pickens has had his ups and downs. Most recently he has been on an up cycle, via his investment firm, BP Capital.
These two gentlemen share an uncanny and proven ability to accurately predict future trends. The only real mistake that I am aware of is Mr. Pickens’ timing regarding natural gas prices some years ago. He was right about the price move, but he was just a little early.
Mr. Rainwater was profiled in the 12/14/05 issue of Fortune Magazine, “The Rainwater Prophecy.” Mr. Rainwater is deeply concerned about Peak Oil. In the article, Mr. Rainwater said, “This is the first scenario I’ve seen where I question the survivability of mankind.” Mr. Rainwater first became concerned about Peak Oil after reading “The Long Emergency” by James Howard Kunstler.
According to Bill McKenzie, with the Dallas Morning News, the primary reason that President Bush used the “Addicted to OIl” phrase in his state of the Union Speech was the Fortune article about Richard Rainwater, and again Mr. Rainwater became concerned about Peak Oil after reading Mr. Kunstler’s book.
On November 1, 2005 the Greater Dallas Planning Council and the Southern Methodist University Environmental Sciences Department cosponsored a symposium featuring Mr. Kunstler and Matthew R. Simmons entitled “The Unfolding Energy Crisis and its Impact on Development Patterns.” Mr. Pickens, via BP Capital, was one of the lead underwriters of the event.
Mr. Pickens, several of his associates, and several other notable Dallas businessmen such as Herbert Hunt were at the Simmons/Kunstler symposium, but no one from your respective editorial and news departments were able to make the event--despite multiple notices of the event.
In any case, Mr. Pickens has publicly stated that he believes that the world is at peak oil production. Mr. Pickens has publicly suggested increasing the gasoline tax, in an attempt to reduce oil consumption, with offsetting tax cuts elsewhere.
I certainly don’t speak for either Richard Rainwater or Boone Pickens, but my impression of these two gentlemen--along with Matt Simmons and Jim Kunstler--is that they are American patriots, in the truest sense of the word, who are trying to warn their fellow Americans about the dangers posed by Peak Oil.
In the Fortune interview, Mr. Rainwater was quoted as follows, “I believe in Hubbert’s Peak. I came out of Texas. I watched oil fields reach peak and go over, and I’ve watched how people would do all they could, put whatever amount of money into the field, and they couldn’t do anything about it.”
Much of the Peak Oil debate is based on pioneering work done by a famous Texas born geoscientist, M. King Hubbert. My coauthor, “Khebab,” and I wrote an article that was published on the Energy Bulletin website, “M. King Hubbert's Lower 48 Prediction Revisited: What can 1970 and Earlier Lower 48 Oil Production Data Tell Us About Post-1970 Lower 48 Oil Production?” Following is an excerpt from that article.
Fifty years ago this week, on March 8, 1956, at a meeting of the American Petroleum Institute in San Antonio, Texas, M. King Hubbert, in the preprinted version of his prepared remarks, had the following statement, "According to the best currently available information, the production of petroleum and natural gas on a world scale will probably pass its climax within the order of a half century (i.e., by 2006), while for both the United States and for Texas, the peaks of production may be expected to occur with the next 10 or 15 years (i.e., 1966 to 1971)." As more and more people are learning, Lower 48 oil production, as predicted by Dr. Hubbert, peaked in 1970, and it has fallen fairly steadily since 1970.
Kenneth Deffeyes, in Chapter Three of his recent book, "Beyond Oil: The View From Hubbert's Peak," described a simplified way of predicting the production peaks for various regions and for their subsequent declines. One simply plots annual production (P) divided by cumulative production to date (Q) on the vertical axis, or P/Q, versus Q on the horizontal axis. Stuart Staniford, on The Oil Drum Blog, has described this technique as "Hubbert Linearization" or HL.
With time, a HL data set starts to show a linear progression, and one can extrapolate the data down to where P is effectively zero, which gives one Qt, or ultimate recoverable reserves for the region. Based on the assumption that production tends to peak at about 50% of Qt, one can generate a predicted production profile for the region. The Lower 48 peaked at 48.5% of Qt.
Using the HL technique, Dr. Deffeyes, an associate of Dr. Hubbert, predicted that the world crossed the mathematical 50% of Qt mark on December 16, 2005. In other words, Dr. Deffeyes believes that the world is now where the Lower 48 was at in the early Seventies.
We used the HL method to predict post-1970 Lower 48 cumulative oil production, using only 1970 and earlier production data. Our work indicated that the HL method was 98.7% accurate in predicting post-1970 Lower 48 cumulative oil production.
We need to differentiate between conventional and nonconventional oil. Perhaps the best way to differentiate the two types of oil is to classify it the following way. Conventional--the oil will move to a wellbore on its own. Nonconventional--the oil and oil-like solids have to be surface mined or heated in order to move to a wellbore (or synthesized from lighter hydrocarbons).
Dr. Deffeyes estimates that we that we have two trillion barrels of recoverable conventional oil reserves worldwide and that we have used half of this amount.
Fossil fuels can be viewed as a continuum, from natural gas, to natural gas liquids, to condensate, to light sweet crude oil to heavy sour crude oil to bitumen to coal. (Kerogen, a precursor to bitumen, can also be processed to yield oil.) This list is a progression from gas, to liquid to solid. It is also a progression from cleanest, natural gas, to dirtiest, coal.
The world wants Liquid Transportation Fuels (LTF’s)--gasoline, diesel and jet fuel. LTF’s can be obtained for the least expenditures of energy and capital from light sweet crude. It only makes sense that light sweet crude will peak before heavy sour, and based on the current historically high spreads between light sweet crude and heavy sour crude, that appears to be the case.
The world is increasingly turning toward the endpoints--natural gas/natural gas liquids on the light end and bitumen/coal on the heavy end--in an attempt to maintain and increase our supply of LTF’s. There are several problems. These are hugely capital intensive programs that tend to produce liquids at very low rates compared to conventional oil sources, and on the heavy end there are some fairly severe environmental consequences. Another point that is often overlooked is that every fossil fuel resource, except for kerogen, is currently being commercially exploited. In other words, we are simply talking about increasing our rate of extraction of our finite fossil fuel resource base in a desperate attempt to maintain the current American way of life of driving $50,000 SUV’s on 50 mile roundtrips to and from $500,000 mortgages.
Currently, the most significant source of nonconventional oil is the tar sands play in Alberta, Canada, where bitumen is being extracted via surface mining or via the injection of steam into deeper beds.
From fossil fuel and nuclear sources, the world currently uses the energy equivalent of a billion barrels of oil (Gb) every five days. The mighty East Texas Oil Field, the foundation of so many Dallas fortunes, the largest oil field in the Lower 48, and the field that was largely responsible for providing the oil to power the Allies victory over the Axis powers in World War II, made about 5.5 Gb. The field is currently producing 1.2 million barrels of water per day, with a 1% oil cut. It took about 75 years to pretty much fully deplete the East Texas Field. In terms of oil equivalent, the Barnett Shale Gas Play in North Texas should ultimately produce, over several decades, on the order of 4-5 Gbe.
The world uses, from nuclear and fossil fuel sources, the energy equivalent of the recoverable reserves in the East Texas oil Field or the Barnett Shale Play in less than 30 days.
In the 4/2/06 Star Telegram, Automotive Journalist Ed Wallace, in the classified advertising section, wrote a rebuttal to the Peak Oil theories. Mr. Wallace’s two basic points: (1) improved technology will increase recoverable conventional reserves by 50% to 3,000 Gb and (2) nonconventional oil sources will add another 3,000 Gb. Therefore, based on Mr. Wallace’s estimates, we have used 1,000 Gb out of a 6,000 Gb resource base.
In the Viewpoints (Op-Ed) section of the Dallas Morning News, similar “cornucopian” energy abundance articles were published last year making basically the same points that Mr. Wallace made.
In regard to the technology issue, this assertion is directly contradicted by our experience in Texas (peaked at 54% of Qt), the overall Lower 48 (peaked at 49% of Qt) and the North Sea (peaked at 52% of Qt). Nothing the industry has tried in these regions has reversed the production declines once about half of the oil reserves were consumed. The reason is best illustrated by the East Texas field, now producing water with a 1% oil cut. What can better technology do to help a field that has watered out?
In regard to the nonconventional sources of oil, Mr. Wallace is primarily focused on the Canadian tar sands and shale oil (kerogen). The tar sands play is a proven commercial success, that is however hugely energy intensive and that is also yielding vast amounts of contaminated waste water. Mr. Wallace cites the most widely used estimate of 175 Gb in recoverable reserves (note that this should be discounted by about 35% to 50% to get net energy equivalent). He also cited a vague estimate by a Shell executive of 2,000 Gb, that can’t be currently recovered. There is one interesting research program testing some new shale oil technologies, but there is nothing commercial yet.
In any case, let’s look at past and current estimates of Canadian tar sands production. In 2003, the US Energy Information Agency (EIA) estimated that total Canadian oil production--driven by increasing tar sands production--would increase by 700,000 BOPD from 2003 to 2005. The reality? Total Canadian oil production fell from 2003 to 2005. The tar sands production fell short of estimates, and the increasing tar sands production the Canadians had could not make up for the decline in conventional Canadian oil production.
The Canadians themselves are estimating that tar sands production will only increase to about three million BOPD (mbpd) in 2016 from one mbpd today. Note that we will probably start losing a net two mbpd to four mbpd in conventional oil production per year, starting this year. Again, note that you have to discount the tar sands production by 35% to 50% to get net energy.
In effect, Mr. Wallace, and the other energy cornucopians see no problem with the $50,000 Hummer, $500,000 mortgage way of life.
Messrs. Rainwater and Pickens disagree. I can’t speak for them, but I assume that they believe that while nonconventional oil will help, it will only serve to slow the rate of decline of total oil production.
Some types of ethanol production (not from corn sources) appear have some possibilities, but there are a number of problems. Among the problems is a basic conflict between land devoted to food production and land devoted to fuel production. By the way, the US is probably now a net food importer. Currently, the US uses up to 10 calories of fossil fuels to produce one calorie of food. Ponder the impact on our food supply of a declining oil supply.
I realize that US media companies are facing severe economic pressures, and I realize that you are heavily dependent on advertising revenues from the housing/auto industries and from related companies. However, in my opinion we have hit the iceberg. The US media can lash themselves to the sinking ship, by failing to face reality, or you can face the reality of finite energy resources and start heading for the lifeboats.
I am supporting a proposal to abolish the Payroll (Social Security + Medicare) Tax and to replace it with an energy tax, principally a tax on liquid transportation fuels. This would unleash powerful economic forces against profligate energy use. Since it is in effect a consumption tax, it would tax those who currently don’t pay the Payroll Tax, by using cash. Instead of taxing payrolls to fund the Social Security and Medicare systems, we would instead tax energy consumption.
Alan Drake, a consulting engineer, has written a compelling article advocating a crash program of electrifying our transportation system, with special emphasis on Urban Rail.
I am working with a small group regarding the possibility of a Fall symposium on the Energy Tax and Urban Rail proposals, and we would be delighted to have support from The Fort Worth Star Telegram and/or The Dallas Morning News.
Note that these two proposals would address: the Social Security/Medicare crisis; the Peak Oil crisis; the loss of farmland due to suburban sprawl and Global Warming issues. We would replace “dumb growth” with “smart growth,” New Urbanism projects along mass transit lines.
In addition, I would at least ask you to give your readers a balanced report on the Peak Oil issue. Two leading citizens of your respective cities--Richard Rainwater and T. Boone Pickens--are deeply concerned about Peak Oil. The stated mission of the Fort Worth Star Telegram is: “Earning the People’s Trust Daily.” I assume that the Dallas Morning New concurs with this mission statement.
In my opinion, the US media have two choices regarding the Peak Oil issue. To paraphrase Winston Churchill, you can now have either your honor or the status quo. If you do nothing regarding Peak Oil, you will soon have neither the status quo nor your honor.
Sincerely,
Jeffrey J. Brown
Fortune: The Rainwater Prophecy
Brown & Khebab: M. King Hubbert's Lower 48 Prediction Revisited
Wallace: A Theory Like Y2K, But For Cars...
Drake: Electrification of transportation as a response to peaking of world oil production
~~~~~~~~~~~~~~~ Editorial Notes ~~~~~~~~~~~~~~~~~~~
Jeffrey J. Brown is an independent petroleum geologist in the Dallas area. He can be contacted at westexas@aol.com .
He encourages readers to borrow freely from his letter and to write their own letters to media organizations.
-BA
by Jeffrey J. Brown
April 2, 2006
Mr. Wesley R. Turner, President & Publisher
Fort Worth Star Telegram
Mr. James H. Moroney , III, Publisher & CEO
The Dallas Morning News
Subject: What Are Two Texas Billionaires,
Richard Rainwater & T. Boone Pickens,
Saying About Peak Oil & Why Aren’t You Listening?
Gentlemen:
I realize that I don’t have to introduce Richard Rainwater and Boone Pickens to you two gentlemen, but for the benefit of those who may not be familiar with Messrs. Rainwater and Pickens, following are brief introductions.
Richard Rainwater is the Texas based businessman who was chiefly responsible for turning the Bass Family’s inheritance of $50 into a $5 billion dollar fortune. Mr. Rainwater was therefore indirectly responsible for the remarkable urban renaissance of downtown Fort Worth, as a result of the Bass family’s massive investments. Mr. Rainwater also had a material role in George W. Bush’s selection as Managing Partner of the Texas Rangers Baseball Team, which launched Mr. Bush on his way to the Governor’s Mansion and then to the White House.
Mr. Pickens, now based in Dallas, has had a long and storied career in the oil and gas industry. Like most Texas oilmen, Mr. Pickens has had his ups and downs. Most recently he has been on an up cycle, via his investment firm, BP Capital.
These two gentlemen share an uncanny and proven ability to accurately predict future trends. The only real mistake that I am aware of is Mr. Pickens’ timing regarding natural gas prices some years ago. He was right about the price move, but he was just a little early.
Mr. Rainwater was profiled in the 12/14/05 issue of Fortune Magazine, “The Rainwater Prophecy.” Mr. Rainwater is deeply concerned about Peak Oil. In the article, Mr. Rainwater said, “This is the first scenario I’ve seen where I question the survivability of mankind.” Mr. Rainwater first became concerned about Peak Oil after reading “The Long Emergency” by James Howard Kunstler.
According to Bill McKenzie, with the Dallas Morning News, the primary reason that President Bush used the “Addicted to OIl” phrase in his state of the Union Speech was the Fortune article about Richard Rainwater, and again Mr. Rainwater became concerned about Peak Oil after reading Mr. Kunstler’s book.
On November 1, 2005 the Greater Dallas Planning Council and the Southern Methodist University Environmental Sciences Department cosponsored a symposium featuring Mr. Kunstler and Matthew R. Simmons entitled “The Unfolding Energy Crisis and its Impact on Development Patterns.” Mr. Pickens, via BP Capital, was one of the lead underwriters of the event.
Mr. Pickens, several of his associates, and several other notable Dallas businessmen such as Herbert Hunt were at the Simmons/Kunstler symposium, but no one from your respective editorial and news departments were able to make the event--despite multiple notices of the event.
In any case, Mr. Pickens has publicly stated that he believes that the world is at peak oil production. Mr. Pickens has publicly suggested increasing the gasoline tax, in an attempt to reduce oil consumption, with offsetting tax cuts elsewhere.
I certainly don’t speak for either Richard Rainwater or Boone Pickens, but my impression of these two gentlemen--along with Matt Simmons and Jim Kunstler--is that they are American patriots, in the truest sense of the word, who are trying to warn their fellow Americans about the dangers posed by Peak Oil.
In the Fortune interview, Mr. Rainwater was quoted as follows, “I believe in Hubbert’s Peak. I came out of Texas. I watched oil fields reach peak and go over, and I’ve watched how people would do all they could, put whatever amount of money into the field, and they couldn’t do anything about it.”
Much of the Peak Oil debate is based on pioneering work done by a famous Texas born geoscientist, M. King Hubbert. My coauthor, “Khebab,” and I wrote an article that was published on the Energy Bulletin website, “M. King Hubbert's Lower 48 Prediction Revisited: What can 1970 and Earlier Lower 48 Oil Production Data Tell Us About Post-1970 Lower 48 Oil Production?” Following is an excerpt from that article.
Fifty years ago this week, on March 8, 1956, at a meeting of the American Petroleum Institute in San Antonio, Texas, M. King Hubbert, in the preprinted version of his prepared remarks, had the following statement, "According to the best currently available information, the production of petroleum and natural gas on a world scale will probably pass its climax within the order of a half century (i.e., by 2006), while for both the United States and for Texas, the peaks of production may be expected to occur with the next 10 or 15 years (i.e., 1966 to 1971)." As more and more people are learning, Lower 48 oil production, as predicted by Dr. Hubbert, peaked in 1970, and it has fallen fairly steadily since 1970.
Kenneth Deffeyes, in Chapter Three of his recent book, "Beyond Oil: The View From Hubbert's Peak," described a simplified way of predicting the production peaks for various regions and for their subsequent declines. One simply plots annual production (P) divided by cumulative production to date (Q) on the vertical axis, or P/Q, versus Q on the horizontal axis. Stuart Staniford, on The Oil Drum Blog, has described this technique as "Hubbert Linearization" or HL.
With time, a HL data set starts to show a linear progression, and one can extrapolate the data down to where P is effectively zero, which gives one Qt, or ultimate recoverable reserves for the region. Based on the assumption that production tends to peak at about 50% of Qt, one can generate a predicted production profile for the region. The Lower 48 peaked at 48.5% of Qt.
Using the HL technique, Dr. Deffeyes, an associate of Dr. Hubbert, predicted that the world crossed the mathematical 50% of Qt mark on December 16, 2005. In other words, Dr. Deffeyes believes that the world is now where the Lower 48 was at in the early Seventies.
We used the HL method to predict post-1970 Lower 48 cumulative oil production, using only 1970 and earlier production data. Our work indicated that the HL method was 98.7% accurate in predicting post-1970 Lower 48 cumulative oil production.
We need to differentiate between conventional and nonconventional oil. Perhaps the best way to differentiate the two types of oil is to classify it the following way. Conventional--the oil will move to a wellbore on its own. Nonconventional--the oil and oil-like solids have to be surface mined or heated in order to move to a wellbore (or synthesized from lighter hydrocarbons).
Dr. Deffeyes estimates that we that we have two trillion barrels of recoverable conventional oil reserves worldwide and that we have used half of this amount.
Fossil fuels can be viewed as a continuum, from natural gas, to natural gas liquids, to condensate, to light sweet crude oil to heavy sour crude oil to bitumen to coal. (Kerogen, a precursor to bitumen, can also be processed to yield oil.) This list is a progression from gas, to liquid to solid. It is also a progression from cleanest, natural gas, to dirtiest, coal.
The world wants Liquid Transportation Fuels (LTF’s)--gasoline, diesel and jet fuel. LTF’s can be obtained for the least expenditures of energy and capital from light sweet crude. It only makes sense that light sweet crude will peak before heavy sour, and based on the current historically high spreads between light sweet crude and heavy sour crude, that appears to be the case.
The world is increasingly turning toward the endpoints--natural gas/natural gas liquids on the light end and bitumen/coal on the heavy end--in an attempt to maintain and increase our supply of LTF’s. There are several problems. These are hugely capital intensive programs that tend to produce liquids at very low rates compared to conventional oil sources, and on the heavy end there are some fairly severe environmental consequences. Another point that is often overlooked is that every fossil fuel resource, except for kerogen, is currently being commercially exploited. In other words, we are simply talking about increasing our rate of extraction of our finite fossil fuel resource base in a desperate attempt to maintain the current American way of life of driving $50,000 SUV’s on 50 mile roundtrips to and from $500,000 mortgages.
Currently, the most significant source of nonconventional oil is the tar sands play in Alberta, Canada, where bitumen is being extracted via surface mining or via the injection of steam into deeper beds.
From fossil fuel and nuclear sources, the world currently uses the energy equivalent of a billion barrels of oil (Gb) every five days. The mighty East Texas Oil Field, the foundation of so many Dallas fortunes, the largest oil field in the Lower 48, and the field that was largely responsible for providing the oil to power the Allies victory over the Axis powers in World War II, made about 5.5 Gb. The field is currently producing 1.2 million barrels of water per day, with a 1% oil cut. It took about 75 years to pretty much fully deplete the East Texas Field. In terms of oil equivalent, the Barnett Shale Gas Play in North Texas should ultimately produce, over several decades, on the order of 4-5 Gbe.
The world uses, from nuclear and fossil fuel sources, the energy equivalent of the recoverable reserves in the East Texas oil Field or the Barnett Shale Play in less than 30 days.
In the 4/2/06 Star Telegram, Automotive Journalist Ed Wallace, in the classified advertising section, wrote a rebuttal to the Peak Oil theories. Mr. Wallace’s two basic points: (1) improved technology will increase recoverable conventional reserves by 50% to 3,000 Gb and (2) nonconventional oil sources will add another 3,000 Gb. Therefore, based on Mr. Wallace’s estimates, we have used 1,000 Gb out of a 6,000 Gb resource base.
In the Viewpoints (Op-Ed) section of the Dallas Morning News, similar “cornucopian” energy abundance articles were published last year making basically the same points that Mr. Wallace made.
In regard to the technology issue, this assertion is directly contradicted by our experience in Texas (peaked at 54% of Qt), the overall Lower 48 (peaked at 49% of Qt) and the North Sea (peaked at 52% of Qt). Nothing the industry has tried in these regions has reversed the production declines once about half of the oil reserves were consumed. The reason is best illustrated by the East Texas field, now producing water with a 1% oil cut. What can better technology do to help a field that has watered out?
In regard to the nonconventional sources of oil, Mr. Wallace is primarily focused on the Canadian tar sands and shale oil (kerogen). The tar sands play is a proven commercial success, that is however hugely energy intensive and that is also yielding vast amounts of contaminated waste water. Mr. Wallace cites the most widely used estimate of 175 Gb in recoverable reserves (note that this should be discounted by about 35% to 50% to get net energy equivalent). He also cited a vague estimate by a Shell executive of 2,000 Gb, that can’t be currently recovered. There is one interesting research program testing some new shale oil technologies, but there is nothing commercial yet.
In any case, let’s look at past and current estimates of Canadian tar sands production. In 2003, the US Energy Information Agency (EIA) estimated that total Canadian oil production--driven by increasing tar sands production--would increase by 700,000 BOPD from 2003 to 2005. The reality? Total Canadian oil production fell from 2003 to 2005. The tar sands production fell short of estimates, and the increasing tar sands production the Canadians had could not make up for the decline in conventional Canadian oil production.
The Canadians themselves are estimating that tar sands production will only increase to about three million BOPD (mbpd) in 2016 from one mbpd today. Note that we will probably start losing a net two mbpd to four mbpd in conventional oil production per year, starting this year. Again, note that you have to discount the tar sands production by 35% to 50% to get net energy.
In effect, Mr. Wallace, and the other energy cornucopians see no problem with the $50,000 Hummer, $500,000 mortgage way of life.
Messrs. Rainwater and Pickens disagree. I can’t speak for them, but I assume that they believe that while nonconventional oil will help, it will only serve to slow the rate of decline of total oil production.
Some types of ethanol production (not from corn sources) appear have some possibilities, but there are a number of problems. Among the problems is a basic conflict between land devoted to food production and land devoted to fuel production. By the way, the US is probably now a net food importer. Currently, the US uses up to 10 calories of fossil fuels to produce one calorie of food. Ponder the impact on our food supply of a declining oil supply.
I realize that US media companies are facing severe economic pressures, and I realize that you are heavily dependent on advertising revenues from the housing/auto industries and from related companies. However, in my opinion we have hit the iceberg. The US media can lash themselves to the sinking ship, by failing to face reality, or you can face the reality of finite energy resources and start heading for the lifeboats.
I am supporting a proposal to abolish the Payroll (Social Security + Medicare) Tax and to replace it with an energy tax, principally a tax on liquid transportation fuels. This would unleash powerful economic forces against profligate energy use. Since it is in effect a consumption tax, it would tax those who currently don’t pay the Payroll Tax, by using cash. Instead of taxing payrolls to fund the Social Security and Medicare systems, we would instead tax energy consumption.
Alan Drake, a consulting engineer, has written a compelling article advocating a crash program of electrifying our transportation system, with special emphasis on Urban Rail.
I am working with a small group regarding the possibility of a Fall symposium on the Energy Tax and Urban Rail proposals, and we would be delighted to have support from The Fort Worth Star Telegram and/or The Dallas Morning News.
Note that these two proposals would address: the Social Security/Medicare crisis; the Peak Oil crisis; the loss of farmland due to suburban sprawl and Global Warming issues. We would replace “dumb growth” with “smart growth,” New Urbanism projects along mass transit lines.
In addition, I would at least ask you to give your readers a balanced report on the Peak Oil issue. Two leading citizens of your respective cities--Richard Rainwater and T. Boone Pickens--are deeply concerned about Peak Oil. The stated mission of the Fort Worth Star Telegram is: “Earning the People’s Trust Daily.” I assume that the Dallas Morning New concurs with this mission statement.
In my opinion, the US media have two choices regarding the Peak Oil issue. To paraphrase Winston Churchill, you can now have either your honor or the status quo. If you do nothing regarding Peak Oil, you will soon have neither the status quo nor your honor.
Sincerely,
Jeffrey J. Brown
Fortune: The Rainwater Prophecy
Brown & Khebab: M. King Hubbert's Lower 48 Prediction Revisited
Wallace: A Theory Like Y2K, But For Cars...
Drake: Electrification of transportation as a response to peaking of world oil production
~~~~~~~~~~~~~~~ Editorial Notes ~~~~~~~~~~~~~~~~~~~
Jeffrey J. Brown is an independent petroleum geologist in the Dallas area. He can be contacted at westexas@aol.com .
He encourages readers to borrow freely from his letter and to write their own letters to media organizations.
-BA
Labels:
Cheap Oil,
Corporate Fraud,
Energy,
Financial Services
$58 Million Settlement Over Vioxx ....Peanuts!!!
Merck Agrees To $58 Million Settlement Over Vioxx Ad Claims
North Carolina will get $1.8 million from the settlement.
Harrisburg, PA -- Merck & Co. has agreed to pay $58 million as part of a multistate settlement of allegations that its ads for the once-popular painkiller Vioxx deceptively played down the health risks.
The agreement announced Tuesday also calls for Merck to submit all new TV commercials for its drugs to the Food and Drug Administration for review before they can be aired.
The civil settlement ends a joint three-year investigation by 29 states, including North Carolina, and the District of Columbia into Merck's advertising practices involving Vioxx, Pennsylvania Attorney General Tom Corbett said.
Vioxx was taken off the market in 2004 after research showed it doubled the risk of heart attacks and strokes. That triggered thousands of lawsuits against Whitehouse Station, N.J.-based Merck. A pending $4.85 billion settlement would end the bulk of those personal injury suits.
Thanks to aggressive marketing through direct-to-consumer television ads begun in 1999, hundreds of thousands of consumers demanded Vioxx prescriptions before doctors had a chance to understand the side effects, Corbett said.
"Consumers need clear information about the risks associated with prescription drugs so that they can make well-informed decisions about their health care," Corbett said.
The FDA does not require drug companies to submit advertisements for advance approval except in cases where it has pursued enforcement actions over false and misleading claims, agency spokeswoman Rita Chappelle said.
The agreement calls for Merck to submit all new TV commercials for its drugs to the FDA for review and follow through with any changes the agency recommends before airing them for seven years. Additionally, for a 10-year period Merck must comply with any FDA recommendations to delay television advertising for newly approved pain medications.
Merck is also prohibited from "ghostwriting," a practice in which people who worked for the company or were otherwise connected to it allegedly wrote positive articles and studies about Vioxx, Corbett said.
Merck is not admitting any wrongdoing under the settlement and defended its marketing of Vioxx in a statement Tuesday.
"Today's agreement enables Merck to put this matter behind us and focus on what Merck does best, developing new medicines," said Bruce Kuhlik, Merck's executive vice president and general counsel.
Corbett's spokesman, Kevin Harley, said the settlement does not require approval by any court.
Democrats in Congress have intensified their scrutiny of the drug industry, expressing support for tighter regulation of consumer-directed drug advertisements, among other things.
Last year, they tried unsuccessfully to pass a law that would ban such advertisements in the three years after a drug's approval. They are expected to make a similar push later this year.
Most of the settlement cost will be covered by a $55 million pretax charge that Merck said it took in the first quarter. Pennsylvania officials could not immediately provide a breakdown of how the $58 million will be divided.
In February, Merck agreed to pay $671 million to settle claims it overcharged the government for Vioxx and three other popular drugs and bribed doctors to prescribe its drugs. The announcement by federal prosecutors was one of the biggest U.S. health care fraud settlements ever.
In addition to Pennsylvania, the states included in Tuesday's settlement are Arkansas, Arizona, California, Connecticut, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Maine, Maryland, Massachusetts, Michigan, Nebraska, Nevada, New Jersey, North Carolina, North Dakota, Ohio, Oregon, South Carolina, South Dakota, Tennessee, Texas, Vermont, Washington and Wisconsin.
Merck shares fell 26 cents to $39.76 in afternoon trading Tuesday.
Source: Associated Press
Copyright: 2008 digtriad.com
North Carolina will get $1.8 million from the settlement.
Harrisburg, PA -- Merck & Co. has agreed to pay $58 million as part of a multistate settlement of allegations that its ads for the once-popular painkiller Vioxx deceptively played down the health risks.
The agreement announced Tuesday also calls for Merck to submit all new TV commercials for its drugs to the Food and Drug Administration for review before they can be aired.
The civil settlement ends a joint three-year investigation by 29 states, including North Carolina, and the District of Columbia into Merck's advertising practices involving Vioxx, Pennsylvania Attorney General Tom Corbett said.
Vioxx was taken off the market in 2004 after research showed it doubled the risk of heart attacks and strokes. That triggered thousands of lawsuits against Whitehouse Station, N.J.-based Merck. A pending $4.85 billion settlement would end the bulk of those personal injury suits.
Thanks to aggressive marketing through direct-to-consumer television ads begun in 1999, hundreds of thousands of consumers demanded Vioxx prescriptions before doctors had a chance to understand the side effects, Corbett said.
"Consumers need clear information about the risks associated with prescription drugs so that they can make well-informed decisions about their health care," Corbett said.
The FDA does not require drug companies to submit advertisements for advance approval except in cases where it has pursued enforcement actions over false and misleading claims, agency spokeswoman Rita Chappelle said.
The agreement calls for Merck to submit all new TV commercials for its drugs to the FDA for review and follow through with any changes the agency recommends before airing them for seven years. Additionally, for a 10-year period Merck must comply with any FDA recommendations to delay television advertising for newly approved pain medications.
Merck is also prohibited from "ghostwriting," a practice in which people who worked for the company or were otherwise connected to it allegedly wrote positive articles and studies about Vioxx, Corbett said.
Merck is not admitting any wrongdoing under the settlement and defended its marketing of Vioxx in a statement Tuesday.
"Today's agreement enables Merck to put this matter behind us and focus on what Merck does best, developing new medicines," said Bruce Kuhlik, Merck's executive vice president and general counsel.
Corbett's spokesman, Kevin Harley, said the settlement does not require approval by any court.
Democrats in Congress have intensified their scrutiny of the drug industry, expressing support for tighter regulation of consumer-directed drug advertisements, among other things.
Last year, they tried unsuccessfully to pass a law that would ban such advertisements in the three years after a drug's approval. They are expected to make a similar push later this year.
Most of the settlement cost will be covered by a $55 million pretax charge that Merck said it took in the first quarter. Pennsylvania officials could not immediately provide a breakdown of how the $58 million will be divided.
In February, Merck agreed to pay $671 million to settle claims it overcharged the government for Vioxx and three other popular drugs and bribed doctors to prescribe its drugs. The announcement by federal prosecutors was one of the biggest U.S. health care fraud settlements ever.
In addition to Pennsylvania, the states included in Tuesday's settlement are Arkansas, Arizona, California, Connecticut, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Maine, Maryland, Massachusetts, Michigan, Nebraska, Nevada, New Jersey, North Carolina, North Dakota, Ohio, Oregon, South Carolina, South Dakota, Tennessee, Texas, Vermont, Washington and Wisconsin.
Merck shares fell 26 cents to $39.76 in afternoon trading Tuesday.
Source: Associated Press
Copyright: 2008 digtriad.com
Saturday, June 30, 2007
Queen of Corporate Bankruptcy Fraud
Darla Moore -- president of the private investment firm Rainwater Inc. -- was named to Fortune's 1999 list of the 50 most powerful women. Along the way she has notched three different careers and earned such distinctions as "the queen of DIP" (debtor-in-possession financing, which Moore pioneered during her highly successful tenure at Chemical Bank), "the toughest babe in business" (emblazoned on a Fortune magazine cover story), and "the best investment I ever made" (attributed to husband Richard Rainwater).
In 1991, Darla Moore married investor Richard Rainwater. In 1993 she became president of Rainwater Inc. According to Fortune, by 1997 she had tripled her husband's net worth, to $1.5 billion.
She started working with the Republican National Committee in Washington, D.C. Politics, she thought then, was synonymous with power and the ability to influence people and events. She attended business school at George Washington University and then joined 30 other MBAs in the training program at Chemical Bank (now Chase).
Moore entered corporate bankruptcy area. The idea was to work with companies that got into financial trouble. At the time there were very few of them, and no one was doing anything remotely like making any money on it.
"I worked in the trenches with these financially distressed companies while the LBO establishment continued to churn out ever bigger, ever more expensive mergers and acquisitions. These people had no concept that there would ever be an economic downturn."
Of course there was, just look at Columbia/HCA, and "America blew up, largely as a result of greed, a total lack of perspective ? and the overleveraging of the corporate environment. I had watched all this going on and thought, 'Keep financing this, boys, because you are just creating business for me,'" Moore says.
She does not mention the fact that greed was FRAUD...
By the early 1990s, Moore had become the highest-paid woman in banking and an extremely tough negotiator. "All of a sudden, this product I had created was the 'product du jour.' Nobody in the country had any kind of infrastructure or knowledge that could address this, other than what I had developed over a several-year period. I was the only person with the expertise, and our area was the only one making any money. It had become a powerful profit center within the bank."
As it did with Columbia/HCA, where Moore eventually fired CEO Rick Scott, a friend of her husband's, after the health care company became the target of a federal criminal investigation. (Richard Rainwater was also an officer at HCA...in cognito)
When the federal government, which accounted for 40% of Columbia's revenues, attempted to get information from the company, "management stonewalled. If that had continued, I believe the fate of Columbia would have been similar to that of Drexel. The government will kill you if they are of mind. They could have killed Columbia just as they did Drexel. That was what created the aggressiveness on my part. We would not have done what we did if the stakes had not been so high -- the potential loss of the whole company. ?
Most materials copyright © 2000 of the Wharton School of the University of Pennsylvania. Published January 2000
In 1991, Darla Moore married investor Richard Rainwater. In 1993 she became president of Rainwater Inc. According to Fortune, by 1997 she had tripled her husband's net worth, to $1.5 billion.
She started working with the Republican National Committee in Washington, D.C. Politics, she thought then, was synonymous with power and the ability to influence people and events. She attended business school at George Washington University and then joined 30 other MBAs in the training program at Chemical Bank (now Chase).
Moore entered corporate bankruptcy area. The idea was to work with companies that got into financial trouble. At the time there were very few of them, and no one was doing anything remotely like making any money on it.
"I worked in the trenches with these financially distressed companies while the LBO establishment continued to churn out ever bigger, ever more expensive mergers and acquisitions. These people had no concept that there would ever be an economic downturn."
Of course there was, just look at Columbia/HCA, and "America blew up, largely as a result of greed, a total lack of perspective ? and the overleveraging of the corporate environment. I had watched all this going on and thought, 'Keep financing this, boys, because you are just creating business for me,'" Moore says.
She does not mention the fact that greed was FRAUD...
By the early 1990s, Moore had become the highest-paid woman in banking and an extremely tough negotiator. "All of a sudden, this product I had created was the 'product du jour.' Nobody in the country had any kind of infrastructure or knowledge that could address this, other than what I had developed over a several-year period. I was the only person with the expertise, and our area was the only one making any money. It had become a powerful profit center within the bank."
As it did with Columbia/HCA, where Moore eventually fired CEO Rick Scott, a friend of her husband's, after the health care company became the target of a federal criminal investigation. (Richard Rainwater was also an officer at HCA...in cognito)
When the federal government, which accounted for 40% of Columbia's revenues, attempted to get information from the company, "management stonewalled. If that had continued, I believe the fate of Columbia would have been similar to that of Drexel. The government will kill you if they are of mind. They could have killed Columbia just as they did Drexel. That was what created the aggressiveness on my part. We would not have done what we did if the stakes had not been so high -- the potential loss of the whole company. ?
Most materials copyright © 2000 of the Wharton School of the University of Pennsylvania. Published January 2000
Who is Richard Rainwater? The man of many faces
Richard Rainwater is more than just the Texas Billionaire who managed a fund in Ft. Worth, Texas.
Richard Rainwater was more than just the Texas Rangers co-partner of George W Bush .
(by the way, he insisted that Bush have no OPERATIONAL control in the organization)
Richard Rainwater is more than just a friend of Richard Scott, the convicted Health Care Executive for fraud. His silent affiliation with HCA/Columbia has yet to be exposed. Frist Family)
In 1991, Darla Moore married investor Richard Rainwater. In 1993 she became president of Rainwater Inc. According to Fortune, by 1997 she had tripled her husband's net worth, to $1.5 billion.
Stay tuned for more......
Richard Rainwater was more than just the Texas Rangers co-partner of George W Bush .
(by the way, he insisted that Bush have no OPERATIONAL control in the organization)
Richard Rainwater is more than just a friend of Richard Scott, the convicted Health Care Executive for fraud. His silent affiliation with HCA/Columbia has yet to be exposed. Frist Family)
In 1991, Darla Moore married investor Richard Rainwater. In 1993 she became president of Rainwater Inc. According to Fortune, by 1997 she had tripled her husband's net worth, to $1.5 billion.
Stay tuned for more......
Subscribe to:
Posts (Atom)